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Abstract 
Background: Uveal melanoma (UM) is an extremely aggressive disease with 
approximately 50% of patients developing incurable metastatic disease. Therefore, 
accurate prognosis of a patient is necessary for closer follow up and the earlier 
implementation of systemic adjuvant therapies in those most likely to develop metastatic 
disease. Fortunately, UM can be classified into two distinct molecular classes based on 
clinically validated gene expression profiling, chromosomal aberrations and specific 
driver mutations, which accurately predict the metastatic propensity of the primary 
tumour. However, genetic testing currently requires biopsy of the eye which can lead to 
serious complications including permanent blindness. Therefore, an alternative source of 
primary tumour genetic material is needed to avoid these complications.  
Aims: We proposed that circulating tumour cells (CTCs) are a viable source of tumour 
genetic material in which patient prognosis could be analysed. Firstly, we aimed to 
increase the sensitivity of an immunomagnetic enrichment protocol to capture CTCs. 
Secondly, we aimed to evaluate whole genome amplification methods for accurate single 
cells analysis to determine the genomic profile of UM cells. The combination of both 
aims would allow the use of UM CTCs for determining disease prognosis from an easily 
accessible blood sample. 
Methodologies: Aim 1 - To refine and evaluate methods for multi-marker 
immunomagnetic capture of UM CTCs.  A tissue microarray (TMA) was created from 
1mm cores taken from archived primary UM tissue. Normal tissue and cutaneous 
melanoma were added as controls. The TMA was stained by immunohistochemistry 
(IHC) for melanoma, melanocyte, and stem cell markers. Stained tissue was assessed to 
determine intensity and coverage of staining. In addition to primary UM tissue, five UM 
cell lines were assessed for the same markers using flow cytometry and 
immunocytochemistry. Given their high level of staining of UM, 5HT2B, ABCB5, 
surface gp100 (BETEB), MCAM, and MCSP were coated to immunomagnetic beads and 
used to determine the retrieval rate of UM cell lines cells spiked into peripheral blood 
mononuclear cells at a known quantity. CTCs could be detected by immunofluorescent 
staining of MART1, gp100, and S100β. 
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Aim 2 - Aim 2: To develop methodologies for the detection of genetic markers of 
metastatic propensity using single UM cells. Single UM cell line cells plus respective 
bulk genomic DNA whole genome amplified and bulk genomic DNA were amplified 
using PicoPlex and Repli-G WGA kits to determine each kits’ respective viability of 
detecting CNVs using low-pass (0.01-0.1x) whole genome sequencing (WGS) on the 
IonPGM platform. Peripheral blood mononuclear cells (PBMCs) were used as negative 
controls. In addition, we tested if these methods allowed accurate CNV data after fixation, 
permeabilisation, and immunostaining. After ensuring cell processing had no significant 
effects on genomic profile of single cells, blood samples from patients were processed to 
isolate CTCs from PBMCs. Isolated CTCs were then whole genome amplified using 
PicoPlex and shallow sequenced using the IonPGM system. 
Results: We validated several melanoma, melanocyte, and stem cell markers which have 
been previously shown to be expressed in cancer, cutaneous melanoma, or UM. We found 
that 5HT2B, and ABCB5, surface gp100 (BETEB), MCAM, and MCSP were highly 
expressed in primary UM tissue or UM cell lines and were able to immunomagnetically 
capture UM cell line cells. Concurrently, we validated the use of shallow (0.01x-0.1x 
depth) whole genome sequencing of single UM cells amplified using the PicoPlex WGA 
Kit and found that PicoPlex offered a robust method of amplifying single cells that have 
undergone immunomagnetic isolation, fixation, staining, and capture whilst retaining the 
original genetic profile of the parent cell line. Upon testing this in a patient, we found a 
gain of chromosome 8 which is an early event in UM tumourigenesis; aneuploidy of 
chromosome 8 is a genetic feature that may, with the aid of future studies, delineate 
patient metastatic risk. 
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Conclusion: Herein we validated several melanoma, melanocyte, and stem cell markers 
to increase the rate and number of CTCs captured from patients with primary UM. We 
then further validated the use of shallow (0.01-0.1x) WGS to detect CNVs in single cells 
amplified using PicoPlex. We have optimised and validated a pipeline, involving 
separation of CTCs from PBMCs via a multi-marker immunomagnetic captured method 
targeting 5HT2B, ABCB5, surface gp100 (BETEB), MCAM, and MCSP and detection 
via immunostaining of MART1, gp100, and S100β. Once isolated and immunostained, 
single CTCs are captured, whole genome amplified using PicoPlex, and sequenced on the 
IonPGM system to detect CNVs relevant to patient prognosis. This easier, more 
accessible way of detecting patient metastatic risk may enable patients to enrol in clinical 
trials, allow doctors to prescribe potential adjuvant therapies, and facilitate closer follow-
up.  
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1.0 Introduction 
Uveal melanoma (UM) is the most common intraocular malignancy in adults 
(McLaughlin et al., 2005). In Australia, it affects approximately 8.55 individuals per 
million per year (Vajdic et al., 2003). After detection of metastasis, 92% of patients die 
within two years. Moreover, approximately 50% of those diagnosed with localised UM 
develop incurable metastatic disease (Kujala et al., 2003). Although the treatment of 
localised UM has improved over the last 30 years, current treatment has little effect on 
the development of metastatic disease and survival rates have not changed (Singh et al., 
2011). 
To improve patient outcomes, detection of those with the highest risk of developing 
metastasis is necessary to implement early treatment interventions. Many cytogenetic 
features are able to accurately predict UM patient prognosis and propensity of the tumour 
to metastasise (Aalto et al., 2001; Harbour et al., 2010; Martin et al., 2013; Onken et al., 
2004; van Raamsdonk et al., 2009; van Raamsdonk et al., 2010). However, current genetic 
analysis of the tumour requires direct biopsy of the eye, which can lead to serious 
complications such as retinal detachment, vitreous haemorrhage, and permanent 
blindness (Pereira et al., 2013). An alternative source of tumour genetic material can be 
found in circulating tumour cells (CTCs) which may allow analysis of the genetic 
determinants of metastatic propensity by means of a ‘liquid biopsy.’ However, current 
methods for the determination of these markers of metastatic disease in UM CTCs need 
to be developed and evaluated. Here we evaluated markers for UM CTC isolation and 
detection, as well as developed methods to determine genetic aberrations within single 
UM CTCs, to produce a robust protocol for determining the metastatic propensity of 
patients with primary UM tumours from a blood test. 
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2.0 Literature Review 
2.1 Structure of the Eye and Uvea 
The eyes are complex, fluid filled organs. They average 24mm in diameter (Martini et al., 
2015) and resemble a small irregular spheroid. Three layers of tissue encase the fluid 
filled cavity; an outer fibrous layer (sclera), an intermediate vascular layer or uvea (iris, 
ciliary body, and choroid) and an inner layer (retina) (Figure 1). 
 
Figure 1: Anatomy of the Eye. Sagittal section of the eye, showing the internal 
structures (Gray, 1918). Structures commonly affected in UM are the iris, ciliary body 
and choroid.   
 
The uveal or vascular layer is comprised of the iris, ciliary body, and choroid.  This layer 
is responsible for the regulation of light entering the eye, a route for blood vessels that 
service the surrounding tissue, secretion and reabsorption of aqueous humour, and the 
control of lens shape (Martini et al., 2015). More importantly, the uveal layer contains 
melanocytes which dictate eye colour and absorption of light (Martini et al., 2015). The 
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malignant transformation of these melanocytes results in the formation of UM from either 
the anterior (iris) or posterior (ciliary body or choroid) uveal tract, with the majority 
arising in the choroid (COMS-20, 2003; McLaughlin et al., 2005). 
2.2 Uveal Melanoma Epidemiology and Clinical Prognosis 
2.2.1 Epidemiology 
UM is the most common intraocular malignancy in adults and the second most common 
form of melanoma (McLaughlin et al., 2005). The incidence of UM differs worldwide. In 
the United States, the incidence is around 5 cases per million (Singh et al., 2011). 
European incidence has a north-south gradient decreasing from >8 in northern countries 
to <2 cases per million in southern countries (Virgili et al., 2007).  In a similar fashion to 
cutaneous melanoma, the incidence of UM in the Australian population is higher than the 
rest of the world with approximately 8.55 per million for UM (Vajdic et al., 2003). The 
age of diagnosis of UM ranges from 6-100 years, with a median age of 62 years (Singh 
et al., 2011). Interestingly, patients ≤20 years of age appear to have significantly higher 
incidence of iris UM compared to those aged ≥21 (Shields et al., 2012). The importance 
of gender in UM is contested in the literature; two studies showed higher incidences of 
UM in males compared to females (Singh et al., 2011; Virgili et al., 2007), while a third 
study did not note any significant difference between the genders (Shields et al., 2012). 
Lastly, Caucasian populations are predominantly affected in comparison to other races 
and ethnicities (Chang et al., 1998; Singh et al., 2011). 
2.2.2 Risk Factors for Primary Uveal Melanoma 
There are several factors that lead to a predisposition in the development of UM, which 
can be divided into host and environmental factors. Host factors may include light eye 
colour, fair skin colour, and the inability to tan (Weis et al., 2006). Additionally, pre-
existing naevi, the naevus of Ota (Shields et al., 2015; Singh et al., 1998; Singh et al., 
2005; Sumich et al., 1998), and germline BAP1 mutations (Goldstein, 2011; Ismail et al., 
2014) increase the risk of developing UM. Environmental factors include exposure to 
ultraviolet (UV) light from arc welding as a significant risk factor, while chronic UV and 
occupational sun exposure are marginal factors (Shah et al., 2005); , latitude and leisurely 
sunlight exposure are not significant risk factors (Shah et al., 2005).  
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2.2.3 Prognosis: Clinical and Histopathological Features 
At the time of initial diagnosis of UM, approximately 4% of patients have detectable 
metastasis (Finger et al., 2005). However, metastasis of UM occurs in approximately 50% 
of all patients (Jovanovic et al., 2013). UM metastasises via haematogenous 
dissemination, with the most common site of metastasis being the liver followed by the 
lungs and bone (COMS-15, 2001). Nevertheless, UM has been shown to metastasise to 
the brain, skin and any other location within the body (COMS-15, 2001). The median 
time from diagnosis of metastasis to death is <6 months, with the death rate of patients 
being 80% within one year, and 92% within two years after detection of metastasis 
(COMS-26, 2005). 
Large tumour basal diameter (Figure 2A) (Kujala et al., 2003) and tumour thickness 
(apical height) (Figure 2B) (Shields et al., 2009) are associated with the development of 
metastatic disease and ultimately with poorer survival (Shields et al., 2007). Similarly, 
the presence of extraocular extensions has also been shown to correlate with increased 
mortality due to its association with increased tumour malignancy and more advanced 
disease (Coupland et al., 2008). However, Coupland et al. (2008) noted that the size of 
the extraocular extensions did not have any impact on mortality. Tumour size is 
incorporated into the COMS staging system (Appendix 8.5) and all of the above clinical 
features are incorporated into AJCC staging system (Appendix 8.6). These are the two 
most common methods of describing the stages of UM, and aid in the determination of 
patient prognosis (COMS-5, 1997; COMS-17, 2001; Kaliki et al., 2015; Shields et al., 
2013). Patient age at time of diagnosis is another predictive feature, with >60 years being 
more closely associated with metastasis and death (Shields et al., 2012). Other clinical 
features of UM that predict prognosis of patients are ciliary body location, tumour colour, 
presence of subretinal fluid and intraocular haemorrhage (Shields et al., 2009). 
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Figure 2: Size and Thickness of Primary Uveal Melanoma Tumours and Their 
Association with Overall Survival. A) Cumulative incidence estimate of melanoma 
mortality based on largest basal diameter of the primary tumour. Adapted from (Kujala 
et al., 2003), and B) cumulative survival probability graph showing the effects of tumour 
apical height on survival. Adapted from (Shields et al., 2009). 
 
Histopathological characteristics of the primary tumour provide information in regards to 
patient outcome and tumour metastatic propensity. Cell type is one distinct prognostic 
factor. There are two major types of cells involved in UM, spindle (Figure 3A and B) 
and epithelioid (Figure 3C). The loss of cohesion, larger and rounder nucleus, coarse 
chromatin, eosinophilic nucleolus, occasional multinucleated cells, and higher mitotic 
rate are all features that distinguish epithelioid cell type from spindle cell type (McLean 
et al., 2004). The presence of the epithelioid cell type by itself or in a mixed morphology 
(Figure 3D) has a significantly worse prognosis than that of the spindle cell type (Paul et 
al., 1962). In addition, the prognosis becomes poorer with increasing numbers of 
epithelioid cells per high power field (Seddon et al., 1987). Another predictor of prognosis 
is tumours with higher mitotic activity (McLean et al., 1977). Ki-67 is used to determine 
mitotic rate and it has been noted that high levels of Ki-67 in UM are associated with 
shorter survival (Karlsson et al., 1996).  
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Figure 3: Haematoxylin-Eosin Staining of Uveal Melanoma Tumours with Distinct 
Cell Types. A-B) Spindle-cell type A and B, C) epithelioid cell type and D) mixed cell 
type. Adapted from images from http://www.eyecalcs.com/DWAN/pages/v9/v9c020.html 
Vascular features are also used in prognostication of patients. The intravascular presence 
of tumour cells is one histopathological prognostic parameter, with UM cell growth into 
vessels inside the tumour and vessels outside the tumour, or in both, are associated with 
a poorer survival than those without (Ly et al., 2010). Another vascular parameter useful 
in predicting the prognosis of patients with UM is the presence of vascular networks. 
Folberg et al. (1992; 1993) identified nine distinct vascular patterns with the presence of 
vascular networks, defined by three back to back vascular loops, correlating with the 
highest risk of metastatic death.  Microvascular density has been also found associated 
with the presence of microvascular loops and networks, epithelioid cells, largest basal 
tumour diameter, and overall survival (Makitie et al., 1999).  
Lastly, the presence of tumour infiltrating lymphocytes can be used to determine 
prognosis. M2 macrophages (CD68+, CD168+, and CD68+ CD168+) are the primary type 
of infiltrating macrophage in UM and have been shown to be increased drastically in 
tumours with monosomy of chromosome 3. M2 macrophages are associated with ciliary 
body involvement, increased microvascular density and significantly poorer prognosis for 
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survival (Bronkhorst et al., 2011). Additionally, class I and II HLA expression are also 
linked to the levels of immune cell infiltration, with lower levels of HLA expression 
correlating with lower levels of tumour infiltrate (de Waard-Siebinga et al., 1996).  
The use of these clinical and histopathological markers as predictors of patient outcomes 
is problematic, due to the broad variability  and no unified staging system (Werdich et al., 
2013). Therefore, the use of genetic markers for the analysis of UM may provide a more 
accurate and objective prediction of the risk of metastatic disease. 
2.3 Molecular Characteristics of Uveal Melanoma 
2.3.1 Gene Expression 
Comparison of gene expression signatures of primary tumour lesions from patients that 
developed metastasis with those that did not, demonstrated that UM can be organised into 
two distinct molecular classes - class I or class II tumours. Each class displays distinct 
clinical prognostic factors (Figure 4). The largest difference in expression comes from 
down-regulation of chromosome 3 genes and up-regulation of chromosome 8q genes 
(Onken et al., 2004). While class I expression reflects that of normal neural crest derived 
melanocytes, class II corresponds with an up-regulation of epithelial genes, causing these 
tumours to exhibit epithelial features such as polygonal cell morphology, up-regulation 
of epithelial cadherin (E-cadherin), colocalization of E-cadherin and β-catenin to the 
plasma membrane, and the formation of cell-cell adhesion and acinar structures (Onken 
et al., 2006). Conversion to this epithelial phenotype may be a precursor of a metastatic 
cell type (Onken et al., 2006). 
These gene expression profiles were used to develop a clinically validated test called 
DescisionDx-UM, incorporating 12 class discriminating genes and three endogenous 
controls (Appendix 8.2) (Harbour and Chen, 2013). The test has a success rate of >97% 
and can be performed on tissue samples obtained by fine needle biopsy, resection, and 
enucleation (Field and Harbour, 2014). The result of this test classifies patients into class 
I or II categories, and guides the intensity of metastatic surveillance and can be used to 
determine whether the patient should be placed directly onto adjuvant systematic therapy 
(Field and Harbour, 2014). 
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Figure 4: Prognostic Differences between Class I and Class II Tumours. Survival 
probability between class I and class II gene expression in 50 UM patients. All deaths 
were caused by melanoma metastasis. Significant differences in survival between the 
classes of tumour were found (P=0.01). Adapted from (Onken et al., 2004). 
 
Whilst the bulk of patients who develop metastasis harbour a class II gene expression 
profile, there are a subset of class I tumours that also give rise to metastasis. Therefore, 
class I tumours are subgrouped into ‘1a’ and ‘1b’ based on the different expression of 
epithelial cadherin (CDH1) and Ras-related protein Rab-31 (RAB31) (Field et al., 2016). 
Moreover, the presence of Preferentially Expressed Antigen in Melanoma (PRAME) 
mRNA is differentially expressed between these two subroups of class I tumours, with 
0% 5 year rate of metastasis of Class IPrame- and 38% of Class IPrame+ (Field et al., 2016).   
The use of gene expression profiling in primary UM can accurately predict the prognosis 
of patients, however, it requires biopsy of the primary tumour within the eye which can 
lead to complications such as vitreous haemorrhage, retinal detachment, and permanent 
blindness (Pereira et al., 2013). 
2.3.2 Chromosomal Aberrations 
UM displays a lack of genomic instability and aneuploidy compared to other cancers 
(Cross et al., 2003; Papadopoulos et al., 2002). Thus, chromosomal abnormalities found 
consistently in UM are thought to be drivers of tumourigenesis rather than unconnected 
random events. Specific chromosomal abnormalities, defining distinct prognostic and 
metastatic risks (Aalto et al., 2001), allow for a more accurate prognosis in comparison 
with current histopathological measures. 
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Monosomy of chromosome 3 is a common genetic aberration found in UM,  occurring in 
approximately 50% of patients (Hoglund et al., 2004). In addition, monosomy 3 is able 
to predict patient prognosis (Figure 5A) (Prescher et al., 1996; Shields et al., 2011; White 
et al., 1998), as tumours with monosomy 3 have a significantly higher rate of metastasis 
when compared to tumours with disomy 3 (Prescher et al., 1996; Tschentscher et al., 
2001). Moreover, monosomy of chromosome 3 is also associated with clinical and 
histopathological features such as large tumour diameter, epithelioid cell type, ciliary 
body involvement, vascular loops (Prescher et al., 1996; Scholes et al., 2003) and an 
inflammatory phenotype (Herwig and Grossniklaus, 2011; Maat et al., 2008). 
 
Figure 5: Worst Survival for Patients with Changes in Chromosome 3 and 8q. A) 
Monosomy 3 (n=43) is a significant prognostic feature when compared to disomy 3 
(n=23) (P<0.0001) in patients B) Patients with normal (n=14), gain, (n=24), or 
amplification (n=28) of 8q show significant differences in survival between the three 
categories (P<0.0001), between normal vs amplification (P<0.0001), between gain vs 
amplification (p=0.00125), however, normal vs gain was only trending toward 
significance (P=0.07). C) Lastly, monosomy 3 combined with 8q amplification (n=24) 
had significantly increased risk of death to metastasis (P=0.011) when compared to 
monosomy 3 combined with 8q gain (n=16) or monosomy 3 combined with normal 8q. 
Adapted from (Versluis et al., 2015).  
 
Chromosome 8 is another non-random chromosomal aberration described in UM. Gains 
in copies of the long arm of chromosome 8 (G8q) can occur through isochromosome 
formation, unbalanced translocations, and gain of a complete chromosome 8, and are 
present in approximately 40% of UM cases (Hoglund et al., 2004), and are associated 
with reduced survival and reduced disease-free interval (Figure 5B) (Sisley et al., 1997). 
Aalto et al. (2001) found that 53% of metastasising primary tumours and 100% of 
metastases harboured gains in 8q. Additionally, deletions in 8p12-22, containing leucine 
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zipper tumour suppressor-1 (LZTS1), were also associated with quicker onset of 
metastasis, and thus higher metastatic efficiency (Onken et al., 2008). Karyotyping has 
shown that monosomy of chromosome 3 and gain of 8q correlate closely with 
metastasising UM, and tumours with a combination of both mutations exhibit a worse 
prognosis than those with each individual aberration alone (Figure 5C) (Dono et al., 
2014; Versluis et al., 2015). Additionally, monosomy of chromosome 3 and gain in 8q in 
UM together with a large basal tumour diameter and extracellular matrix patterns show 
significantly reduced metastasis free survival (van Beek et al., 2014). 
Chromosome 6 is another prognostically relevant marker in UM. Losses in 6q are 
associated with a poorer prognosis (Aalto et al., 2001). Inversely, gain in 6p is associated 
with a better prognosis (Damato et al., 2009; White et al., 1998). Additionally, the gain 
of 6p and monosomy of chromosome 3 appear to be mutually exclusive, with only 4% of 
cases showing monosomy of chromosome 3 and gain of 6p, although, no prognostic 
information was derived from this finding (Ehlers et al., 2008).  
Loss of heterozygosity of chromosome 1p is an indicator of poor prognosis in tumours 
that also show concurrent monosomy of chromosome 3 (Hausler et al., 2005; Kilic et al., 
2005). In particular, chromosome 1p36 primarily modified the survival of patients with 
monosomy of chromosome 3, with patients who harboured both losses having 7.8 times 
the risk of developing metastases (Kilic et al., 2005). Chromosome 1p loss also occurs in 
40% of tumours with monosomy 3, and in 10% of tumours with disomy 3 (Hausler et al., 
2005). Identification of genes on 1p31 showed reduced expression of Integrin Beta 3 
Binding Protein (ITGB3BP), while expression of Phosphodiesterase 4B (PDE4B), and 
Interleukin 12 Receptor Subunit Beta 2 (IL12RB2) was absent in tumours with monosomy 
3, indicating that these genes may influence progression of UM but are unlikely to be 
driver mutations (Hausler et al., 2005). 
Chromosomal aberrations are powerful tools for the determination of metastatic 
propensity. A simple clinically validated test that is able to accurately determine copy 
number variations is the multiplex ligation-dependant probe analysis (MLPA), with 
results being highly predictive of patient survival (Damato et al., 2010; Lake et al., 2011; 
Vaarwater et al., 2012). However, as for gene expression profiling, biopsy of the primary 
tumour is required, and in addition to complications of the eye, various factors can affect 
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the assessment of chromosomal aberrations, particularly a tumour’s cellular heterogeneity 
and sampling errors, resulting in normal disomy 3 cells diluting tumour derived 
monosomy 3 cells  (Damato et al., 2009). For example, fine needle aspiration biopsies 
may miss the most aggressive parts of a tumour due to the heterogeneous nature of tumour 
cells, impacting the results of chromosomal aberration prognostic testing techniques such 
as MLPA (Damato et al., 2009) or fluorescence in situ hybridisation (Chang et al., 2013; 
Mensink et al., 2009). 
2.3.3 Genes Mutated in Uveal Melanoma 
2.3.3.1 GNAQ and GNA11 
Mutations in Guanine nucleotide-binding protein subunit α-Q (GNAQ) and Guanine 
nucleotide-binding protein subunit α-11 (GNA11) are common in UM (van Raamsdonk 
et al., 2010), which are found at 9q21.2 and 19p13.3 (Versluis et al., 2015). These genes 
encode similar Gqα subunits that consist of helical and catalytic GTPase domains (Figure 
6) (Harbour and Chao, 2014).  
Mutations to these genes cause the encoded receptor to be locked in an active state (van 
Raamsdonk et al., 2010). The constitutive activation of this receptor causes activation of 
the mitogen-activated protein kinase (MAPK) pathway (Bauer et al., 2009), a pathway 
found activated in cutaneous melanoma (Zuidervaart et al., 2005). The MAPK pathway 
is a key regulatory pathway that controls embryogenesis, cell differentiation, cell 
proliferation, and cell death (Pearson et al., 2001). 
 
 
Figure 6: GNAQ and GNA11 Protein Map and Location of Somatic Mutations in 
Uveal Melanoma. GNAQ and GNA11 protein domains. Commonly mutated sites in UM 
are indicated. Adapted from (Harbour and Chao, 2014). 
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GNAQ and GNA11 somatic mutations appear to be mutually exclusive (Harbour and 
Chao, 2014), with 83% of UM harbouring mutations in either gene (van Raamsdonk et 
al., 2010). Two locations for driver mutations, within the switch regions, have been 
described (Figure 6) (van Raamsdonk et al., 2009; van Raamsdonk et al., 2010), with 
GNAQ harbouring Q209P, Q209L, Q209R (Bauer et al., 2009), or R183Q mutations (van 
Raamsdonk et al., 2010). Similarly, GNA11 harbours Q209L, Q209P, R183C, or R183H 
mutations (van Raamsdonk et al., 2010). The GNAQ and GNA11 Q209 mutations are 
found in approximately 45% and 32% of primary UM, and in 22% and 57% of UM 
metastases respectively (van Raamsdonk et al., 2010). R183 mutations in GNAQ or 
GNA11 are found in approximately 2% and 3% of primary UM respectively, and in 6% 
of metastases (van Raamsdonk et al., 2010).  
Mutations in either GNAQ or GNA11 are found in all stages of UM, but show no 
correlation with patient survival (Koopmans et al., 2013). As further evidence for this 
lack of correlation, mutations in either gene can be found in benign blue naevi (van 
Raamsdonk et al., 2009). GNAQ and GNA11 mutations are thought to be early or initiating 
events in UM tumourigenesis, and are found in class I and II tumours (Harbour et al., 
2013), supporting the fact that they alone are not responsible for metastasis.  
2.3.3.2 PLCB4 
Phospholipase C Beta 4 (PLCβ4) is located on chromosome 20p12. The encoded protein 
is responsible for the hydrolysis of phosphatidylinositol 4,5-bisphosphate into 1,4,5-
inositol trisphosphate and 1,2-diacylglycerol, vital components of signal transduction in 
the light response in vertebrate retinas (Alvarez et al., 1995; Anderson and Brown, 1988). 
The synthesised 1,4,5-inositol trisphosphate is now free to diffuse and binds to its 
associated receptor causing increased intracellular Ca2+ levels, whilst 1,2-diacylglycerol 
remains associated to the membrane, and with increased Ca2+ levels causes the activation 
of protein kinase C (Lyon and Tesmer, 2013). This has been associated with cell 
proliferation and survival (Lyon and Tesmer, 2013), and is a downstream target of 
GNAQ/GNA11 (Johansson et al., 2016; Lyon and Tesmer, 2013).  
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Recently, deep sequencing of UM revealed recurrent mutations (D630Y) in PLCβ4s 
highly conserved Y domain (Figure 7) responsible for transduction of extracellular 
signals in approximately 7% of samples. Mutant PLCβ4 were mutually exclusive to 
GNAQ and GNA11 mutations (Johansson et al., 2016).  
 
Figure 7: PLCβ4 Protein Map and Location of Somatic Mutations in Uveal 
Melanoma. PLCβ4 protein domains with the location of the D630 driver mutation. 
Adapted from UniProt. 
2.3.3.3 CYSLTR2 
Cysteinyl leukotriene receptor 2 (CYSLTR2) is found on chromosome 13q14. It is a seven 
transmembrane G protein coupled receptor, and known activator of GNAQ (Evans, 2002; 
Sakmar, 2002). 
Recurrent mutations in CYSLTR2 were recently discovered in UM at codon L129 with a 
substitution of L129Q, located in helix 3 (H3)  (Figure 8), which is part of the receptor 
that contacts the extracellular ligand, associates with other helixes, and interacts with the 
Gα subunit intracellularly causing its constitutive activation (Moore et al., 2016). In this 
same study, it was found that CYSLTR2 mutations followed the same mutual exclusivity 
pattern found in GNAQ, GNA11, and PLCβ4 and were mutated in approximately 3% of 
samples (Moore et al., 2016). Overall, mutations in GNAQ/GNA11, PLCβ4, and 
CYSLTR2 are mutually exclusive and are all confined to the same proliferative pathway, 
resulting in its constitutive activation (Figure 9). 
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Figure 8: CYSLTR2 Protein Map and Location of Somatic Mutations in Uveal 
Melanoma. CYSLTR2 protein domains and the location of L129Q somatic mutation. 
Adapted from UniProt.  
 
             
Figure 9: Interactions between Four Common Genes with Recurrent Mutations.  
GNAQ/GNA11, PLCβ4, and CYSLTR2 protein interactions. Adapted from (Moore et al., 
2016). 
 
2.3.3.4 BAP1 
Another commonly mutated gene in UM is BRCA1 associated protein 1 (BAP1) which 
encodes a nuclear ubiquitin carboxy-terminal hydrolase (UCH) (Jensen et al., 1998). The 
protein consists of UCH catalytic domain, BARD1 binding domain, HCF1 binding motif 
(HBM), BRCA1 binding domain (B), and nuclear localization sequences (NLS) (Figure 
10) (Harbour and Chao, 2014).  
15 
 
 
 
Figure 10: BAP1 Protein Map and Location of Somatic Mutations in Uveal 
Melanoma. BAP1 protein domains with somatic mutation profile in UM. Non-truncating 
mutations (small bars) and truncating mutations (large bars) are displayed. Adapted from 
(Harbour and Chao, 2014) and UniProt. 
 
UCHs are part of the deubiquitinating enzyme protein subfamily (Nishikawa et al., 2009). 
There are four known members of the UCH subfamily: UCH-L1, UCH-L3, UCH37, and 
BAP1 (Misaghi et al., 2009). Breast cancer 1 (BRCA1) is a tumour suppressor gene that 
when transcribed, helps mediate the repair of double strand DNA breaks, chromatin 
remodelling, cell cycle checkpoints, transcription, apoptosis, and centrosome duplication 
regulatory functions. BAP1 interacts with the RING finger domain of BRCA1, with the 
suggestion that BAP1’s carboxyl-terminus is bound to BRCA1 leaving the UCH catalytic 
domain free to interact with ubiquinated, or other ubiquitin like, substrates to remove 
them from the proteasome complex (Jensen et al., 1998). BAP1 binding to BRCA1 is 
shown to increase the cell growth suppressive qualities of BRCA1 (Nishikawa et al., 
2009). In addition to binding to BRCA1, the BAP1 enzyme removes ubiquitin moieties 
from histone H2A and host cell factor 1 (HCF1) (Harbour and Chao, 2014). It is also 
noted that although ubiquitin can be used to direct proteins for degradation, BAP1 appears 
to also affect gene expression, cell cycle, and cellular identity (Eletr and Wilkinson, 2011; 
Harbour and Chao, 2014). The BAP1 protein is a tumour suppressor, and is found 
inactivated in other cancers (Misaghi et al., 2009). Most importantly, repair of double 
strand breaks is the mechanism by which BAP1 exerts its tumour suppressing activity 
(Yu et al., 2014). 
Mutations affecting the protein encoded by BAP1 were found in 84% of class II 
metastasizing UM tumours, and cause premature protein termination or affect the 
ubiquitin carboxyl terminal hydrolase domain (Figure 10). Class I tumours were shown 
to rarely have BAP1 mutations (Harbour et al., 2010). BAP1 is found at 3p21.3 (Jensen et 
al., 1998), so the loss of chromosome 3 could explain the known relationship between 
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loss of heterozygosity (LOH) of chromosome 3 and metastasis of UM, with BAP1 
undergoing inactivating mutations in one copy, and loss of the other copy by 
chromosomal deletions (Harbour and Chao, 2014). 
3.3.5 SF3B1 
Splicing factor 3B, subunit 1 (SF3B1) is located at 2q33.1 (Yang et al., 2013) and the 
protein consists of a U2AF2 interaction motif, PPP1R8 binding domain, SF3B14 
interaction motif, and 22 non redundant HEAT domains (Figure 11) (Harbour and Chao, 
2014; Wang et al., 1998). SF3B1 has been implicated more recently in UM. This gene 
has been shown to harbour driver mutations in its HEAT domains, consisting of single 
nucleotide point mutations primarily at amino acid R625 (Figure 11) (Harbour et al., 
2013; Martin et al., 2013), encoding R625H (63%), R625C (27%), R625G (5%), and 
R625L (5%) mutations (Harbour et al., 2013).  
 
Figure 11: SF3B1 Protein Map and Location of Somatic Mutations in Uveal 
Melanoma. SF3B1 protein domain with the mutation profile of driver mutations found 
in UM. The most common mutation site is noted by the large pin and less common 
mutation sites by the small bars. Adapted from (Harbour and Chao, 2014; Wang et al., 
1998), and UniProt. 
 
The mutations are usually heterozygous and are generally mutually exclusive with BAP1 
mutations but occur with equal frequency in GNAQ versus GNA11 mutated tumours. 
Mutations in SF3B1 are associated with class 1b tumours (Field et al., 2016), and disomy 
of chromosome 3 which is associated with a lower risk of metastasis (Tschentscher et al., 
2001) and better survival rates (Prescher et al., 1996).  
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2.3.3.6 EIF1AX 
Eukaryotic translation initiation factor 1A, X-linked (EIF1AX) is located at Xp22 (Martin 
et al., 2013). It encodes a protein responsible for the transfer of the Met-tRNAf to 40 S 
ribosomal subunits prior to mRNA binding to form the 40S pre-initiation complex 
(Chaudhuri et al., 1997). The protein consists of an N-terminal tail, oligonucleotide 
binding (OB) fold, and C-terminal tail (Figure 12) (Harbour and Chao, 2014). 
Mutations in EIF1AX has been reported in cases of UM as hemizygous missense 
mutations in tumours with disomy of chromosome 3, with all mutations causing in-frame 
changes that affect the N-terminus of the protein (Figure 12) (Martin et al., 2013). In 
addition, tumours with EIF1AX mutations lacked SF3B1 mutations (Martin et al., 2013), 
indicating that these mutations are mutually exclusive. Furthermore, it has been shown 
that only mutant EIF1AX mRNA transcripts are expressed, pointing to epigenetic 
inactivation of the wild-type copy of EIF1AX (Harbour and Chao, 2014). As for SF3B1 
mutations, EIF1AX is associated with class I tumours (Harbour and Chao, 2014), disomy 
of chromosome 3 (Martin et al., 2013), and better prognosis (Harbour and Chao, 2014). 
 
Figure 12: EIF1AX Protein Map and Location of Somatic Mutations in Uveal 
Melanoma. EIF1AX protein domain with the mutation profile of driver mutations in UM. 
Small bars indicate small substitutions or deletions of 1-2 amino acids in the N-terminal 
tail. Adapted from (Harbour and Chao, 2014). 
 
Almost 100% of UM harbour a hotspot mutation in either GNAQ, GNA11, PLCβ4, or 
CYSLTR2. Although they offer no information regarding patient prognosis, they present 
a marker for use in methods such as droplet digital PCR (ddPCR), which is able to detect 
mutations found in cell-free and circulating tumour DNA (cfDNA and ctDNA 
respectively). Previous research has shown ctDNA correlates closely with tumour burden 
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(Ascierto et al., 2013; Sanmamed et al., 2015), this enables ctDNA to work as a surrogate 
biopsy for measuring tumour burden. 
These key mutations and chromosomal aberrations assist not only with the diagnosis of 
UM, but also with prediction of metastatic propensity. Routine identification of these 
mutations may allow clinicians to determine the optimal treatment regimen for each 
individual patient. Examples of this are targeted therapies in cutaneous melanoma, with 
genetic testing of mutations in v-Raf murine sarcoma viral oncogene homolog B (BRAF) 
used in the determination of first-line treatment options (Spagnolo et al., 2015), and in 
UM many clinical trials are using genetic mutations as rational for targeted treatment 
therapies (Appendix 8.3). 
2.4 Uveal Melanoma Treatments 
Radiation or enucleation are the main treatment options for localised UM, with the 
majority of patients undergoing radiation treatment, saving enucleation for patients with 
large tumours in which radiation cannot reduce the tumour sufficiently (Yonekawa and 
Kim, 2012). Brachytherapy is the most common method used for treatment of choroidal 
melanoma (COMS-19, 2002); this method involves suturing a radioactive plaque onto the 
sclera, positioned behind the primary tumour for localised irradiation (Yonekawa and 
Kim, 2012). 
 Proton beam irradiation is the next most common treatment option, and unlike 
brachytherapy, the radiation is highly localised. Regression of tumours is shown by about 
six months, and regression continues following this time (Wilkes and Gragoudas, 1982). 
Recurrence rates are lower in patients receiving proton beam treatment (COMS-19, 
2002). Radiation retinopathy leading to blindness is one complication of radiation 
therapy, where radiation causes endothelial damage and capillary occlusion, resulting in 
retinal haemorrhage, macular oedema, vascular sheathing, microaneurysms, retinal 
exudation, telangiectasia, retinal pigment epithelial atrophy, and cotton wool spots 
(COMS-30, 2009).  
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The use of systemic chemotherapies, to treat metastatic UM, appears to have no benefit. 
Combinations of lomustine, hydroxyurea, dacarbazine, Bacillus Calmette-Guerin 
vaccine, zinostatin, dibromodulcitol, dihydroxy anthracenedione, and aziridinyl 
benzoquinone have been trialled, however, no patients with metastatic ocular melanoma 
responded to treatment (Albert et al., 1996). As UM has a propensity to metastasise to the 
liver, several regional treatments of metastasis have been explored. These include liver 
resection (Mariani et al., 2009), chemo-embolisation (Sharma et al., 2008), and isolated 
hepatic perfusion (Ben-Shabat et al., 2015).  
The use of therapies targeted to specific mutant proteins has been lacking until recently, 
due to unknown mutations in UM. However, this is now changing as a result of recent 
findings, with many targeted therapies entering clinical trials (Appendix 8.3) (Harbour 
and Chao, 2014). One example of recent advances in targeted therapies includes drugs 
targeting the Mitogen-activated protein kinase kinase (MEK) protein downstream of 
GNA11 and GNAQ (Harbour and Chao, 2014); a recent phase II trial using a MEK 
inhibitor extended progression free survival in patients by nine weeks when compared to 
standard temozolomide chemotherapy (Selumetinib, 2013). Using histone deacetylase 
inhibitors may be another potential therapeutic strategy. Recently, it was shown that 
histone deacetylase inhibitors in cells with loss of BAP1 induced morphological 
differentiation, cell cycle exit, and reversion to melanocytic gene expression profile in 
UM cell lines (Landreville et al., 2012).  
Ipilimumab immunotherapy has also recently been used in the treatment of UM. A recent 
phase II trial of ipilimumab in advanced UM patients showed median overall survival of 
6.8 months compared to median overall survival of <6 months without treatment, with 
47% of patients having stable disease, and none experiencing partial or complete response 
(COMS-26, 2005; Zimmer et al., 2015). A retrospective study of local treatments 
including ipilimumab, bevacizumab and kinase inhibitors was performed at the Mayo 
clinic. It was found that localised therapies were the only therapies to significantly 
improve survival, although, the patients in the trial had better prognostic markers at 
diagnosis of metastasis (Moser et al., 2015).  
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Ipilimumab, bevacizumab, and kinase inhibitors had a positive effect on survival, but did 
not reach statistical significance when used in patients with metastatic disease (Moser et 
al., 2015). Another immunotherapy involves targeting programed death receptor 1 (PD-
1) and programed death ligand 1 (PD-L1). A recent trial evaluated the efficacy of PD-1 
blockade in patients with metastatic UM. Out of 58 patients, only 2 (3.6%) had an 
objective response and 5 (9%) patients had stable disease for ≥6 months. The median 
progression free and overall survival were 2.6 and 7.6 months respectively (Algazi et al., 
2016). The poor response to immunogenic therapies may indicate that UM lacks the 
immunogenicity found in other tumour types susceptible to immunotherapies. A recent 
study investigated the immunologic composition of UM metastasis, and found that the 
UM tumour infiltrating lymphocytes were CD4+ dominant, with discovery of a small 
subset of UM patients harbouring more antitumour infiltrating lymphocytes, comparable 
to patients with cutaneous melanoma, and correlating to the level of pigmentation found 
in the tumour using MRI (Algazi et al., 2016). Therefore, overall outcomes may improve 
in patients with this small subset of immunogenic UM, if detected and treated via 
immunotherapies.  
Patient death occurs from metastasis of the primary tumour. In addition to the treatment 
information described above, previous reports have evaluated the effects of treatments for 
patients with metastatic disease and found no compelling evidence to suggest that 
treatment of patients with UM provides any survival benefit (Augsburger et al., 2009). 
Therefore, implementation of adjuvant therapies to prevent metastasis, or to manage 
progression of microscopic or macroscopic metastasis may be required to improve patient 
outcomes. 
A literature review of historical randomised and non-randomised trials for adjuvant 
therapies (6 therapy types, from 1990-2009) revealed no difference in survival outcomes 
post adjuvant therapies. However, these trials predate routine genetic testing currently 
used to predict patient prognosis, and may not be targeting patients at a high risk of 
metastasis, and therefore may be statistically underpowered (Triozzi and Singh, 2014). 
Current adjuvant therapy trials pre-screen patients based on the genetic profile of the 
primary tumour, to identify those at a high risk of developing metastases. Review of 
clinicaltrials.gov reveals 4 active studies (Appendix 8.4) that attempt to prevent 
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metastasis, and one study that aims to prevent metastatic recurrence using tyrosine kinase 
inhibitors, cytotoxic chemicals or through biological interventions.  
Another literature review suggests that other drugs may be also be useful as adjuvant 
therapies, particularly histone deacetylase inhibitors (Landreville et al., 2012), DNA 
methyltransferase inhibitors (Alcazar et al., 2012; Triozzi et al., 2012), MAPK inhibitors 
(Kirkwood et al., 2012), or MEK/tyrosine-protein kinase Met (MET) inhibitors 
(Chattopadhyay et al., 2014), due to their effects in either in vitro studies against UM cell 
lines or in pre-clinical trials. It is expected that some of these therapies will be tested in 
clinical trial in the near future. This underscores the need for methodologies to enable 
stratification of metastatic risk in the majority of patients with localised uveal melanoma. 
2.5 Circulating Tumour Cells 
2.5.1 Features, Identification, and Capture of Circulating Tumour Cells 
Circulating tumour cells (CTCs) are tumour cells that have circulated into the peripheral 
blood of cancer patients, mediating metastatic dissemination. There are many studies 
evaluating the prognostic value of CTCs in patients with a variety of cancers. In metastatic 
prostate cancer (de Bono et al., 2008) for example, varying stages of small-cell lung 
cancer (Hou et al., 2012), metastatic colorectal cancer (Cohen et al., 2008), and metastatic 
breast cancer (Cristofanilli et al., 2004), higher levels of CTCs were associated with 
significantly reduced overall survival. Furthermore, CTCs are now recommended by the 
American Society of Clinical Oncology for the clinical staging of breast cancer (Harris et 
al., 2007). 
As the presence of CTCs has proven useful in determination of prognosis in other cancers, 
investigation of CTCs in patients with UM may be a useful prognostic marker. Originally 
detection of CTCs via reverse transcriptase-polymerase chain reaction (RT-PCR) was a 
common method, targeting Tyrosinase (Boldin et al., 2005), MART1 (Schuster et al., 
2007), and gp100 (Keilholz et al., 2004) mRNA in either a single or multi-marker 
approach. However, RT-PCR is an indirect measure of the presence of CTCs and cannot 
be used to concurrently demonstrate the presence of CTCs, nor does it provide genotypic 
and phenotypic information of the CTCs Moreover, RT-PCR cannot differentiate 
between CTCs and circulating RNA, and is prone to high background and nonspecific 
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amplification (Kowalewska et al., 2006; Paterlini-Brechot and Benali, 2007). Therefore, 
immunomagnetic methods of detecting CTCs were developed to allow for the isolation 
of intact cells.  
By targeting melanoma-associated chondroitin sulphate proteoglycan (MCSP) 
conjugated to immunomagnetic beads, 1-5 CTCs were detected in 50 mL of peripheral 
blood in 19% (10/52) of patients with primary UM (Ulmer et al., 2008). The presence of 
the CTCs was associated with ciliary body invasion, advanced tumour stage, tumour basal 
diameter >14mm, and anterior tumour localization, which are all noted features in UM 
progression (Ulmer et al., 2008). Similarly, another study showed that 14% (13/94) of 
patients with primary UM have detectable CTCs prior to treatment (Suesskind et al., 
2011). However, Suesskind et al. (2011) found that there was no association between the 
levels of CTCs and the propensity of the tumour to metastasise over a short median 
follow-up of 16 months.  
The use of immunomagnetic beads coated with melanoma cell adhesion molecule 
(MCAM) for CTC isolation, followed by detection with MCSP immunostaining to 
confirm CTC status, increased the rate of CTC detection (50%) in primary UM patients, 
with more than 1 CTC captured per 7.5mL of blood (Bande et al., 2015). Interestingly, 
Band et al. (2015) noted that a higher level of CTCs (3/7.5mL) was found in a patient 
with a larger UM that harboured extrascleral extension and epithelioid pathology. 
Nevertheless, a single marker approach for CTC isolation is not sufficient for detecting 
CTCs in all patients.  
To overcome the low sensitivity of a one marker approach, a dual immunomagnetic 
enrichment protocol was developed. Using two antibodies recognising the melanoma 
markers CD63 and glycoprotein 100 (gp100) (NKI/C3 and NKI/BETEB respectively) 
enabled the detection of CTCs in 94% (29/31) of patients with a median cell density of 
3.5 cells per 10 mL of blood, with a cell range of 0-10.2 cells (Tura et al., 2014). In a 
follow-up study, 91% of patients (40/44) were found to have a median cell density of 2.4 
per 10 mL of blood, with a range of 0-10.2 cells (Tura et al., 2016). 
More recently, filtration based protocols have been described. As CTCs are generally 
larger than surrounding leukocytes (Mazzini et al., 2014) they are able to be collected via 
size based filtration. When this method was used, UM CTCs were identified in 
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approximately 50% (15/29) of patients with localised disease. The presence of CTCs did 
not associate with any clinical or pathological parameter, however, it was found that >10 
CTCs per 10 mL of blood was a negative prognostic marker of disease-free and overall 
survival over a 24 month period (Mazzini et al., 2014). As this method filters on the basis 
of size, CTCs that are too small may be missed or normal cells that are clumped together 
may be kept. 
The levels of CTCs in the peripheral blood have provided conflicting results in the 
determination of patient prognosis. Independent of the prognostic value of CTC 
quantification, genetic testing of well characterised prognostic markers in individual 
CTCs may provide more reliable information. However, the rate of CTC retrieval in 
patients requires improvements. 
Table 1: Additional Potential Markers for Use in Immunomagnetic Capture of 
Uveal Melanoma Circulating Tumour Cells 
Name Site (Potential Use) Description 
ATP-binding cassette sub-
family B member 5 
(ABCB5) 
Membrane 
(Capture) 
In UM, ABCB5 is expressed in both pigmented and non-pigmented cells, with ABCB5 
having preferential expression at the leading edge of the tumour (Thill et al., 2011). 
ABCB5 is expressed in cutaneous melanoma CTCs (Freeman et al., 2012; Gray et al., 
2015a). 
CD271 (NGFR) Membrane 
(Capture) 
In UM, 3D cell culture conditions that facilitated vascular mimicry patterns expression 
of CD271 was observed (Valyi-Nagy et al., 2012). CD271 is also expressed in cutaneous 
melanoma CTCs (Freeman et al., 2012; Gray et al., 2015a). 
5-Hydroxytryptamine 
receptor 2B (5HT2B)  
Membrane 
(Capture) 
In UM, expression profiling showed 5HT2B was significantly upregulated in UM liver 
metastases (Zhang et al., 2014) and is one of the class discriminating genes in the 
DecisionDx-UM test (Harbour and Chen, 2013). Its expression in cutaneous melanoma 
or associated CTCs is unknown. 
Receptor activator of NF- 
κB (RANK) 
Membrane 
(Capture) 
In cutaneous melanoma, RANK is involved in migration and metastasis of tumour 
epithelial cells (Kupas et al., 2011), and is expressed in CTCs (Freeman et al., 2012; 
Gray et al., 2015a; Kupas et al., 2011). Its expression in UM is unknown. 
Melanoma associated 
antigen 3 (MAGEA3) 
Membrane 
(Capture) 
MAGEA3 is expressed in approximately 50% of cutaneous melanoma (Vourc'h-
Jourdain et al., 2009) and associated CTCs (Hoshimoto et al., 2012). It has not been 
tested in UM or UM CTCs. 
Nestin Intracellular 
(Quantification) 
Cytoplasmic Nestin staining is positive in 76% of cells, predominantly in nonpigmented 
cells in UM (Thill et al., 2011), and in cutaneous melanoma CTCs (Fusi et al., 2011). 
Melanoma antigen 
recognised by T cells 
(MART1) 
Intracellular 
(Quantification) 
MART1 is expressed by melanoma cells and melanocytes with high levels in early stage 
melanosomes and associates with differentiation and melanogenesis (Zhang et al., 
2013). It is expressed in cutaneous melanoma CTCs (unpublished data), and in UM 
CTCs (Schuster et al., 2011). 
S100 Intracellular 
(Quantification) 
S100 is detected in cells at all stages of liver metastasis in UM (Grossniklaus, 2013). It 
is also a melanogenesis marker. 
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A multi-marker immunomagnetic bead approach for CTC capture and collection has been 
described by our lab in cutaneous melanoma (Freeman et al., 2012). This approach to 
CTC collection provided a considerable improvement in the sensitivity of CTC collection, 
in comparison with single marker approach (Freeman et al., 2012). Current literature 
describing markers for immunomagnetic capture of UM is limited, with studies using 
either MCSP (Suesskind et al., 2011; Ulmer et al., 2008), MCAM (Bande et al., 2015; 
Bidard et al., 2014), or gp100 (Tura et al., 2014) for isolating CTCs, and two different 
markers for quantification by immunostaining of captured CTCs, including MCSP 
(Bidard et al., 2014; Suesskind et al., 2011; Tura et al., 2014; Ulmer et al., 2008), and 
gp100 (Tura et al., 2014).  
Although MCSP has been shown to be expressed in 95% of primary UM (Li et al., 2003), 
and although the specificity of MCSP is high, to improve sensitivity, targeting of 
additional or other markers expressed in UM CTCs may be required to improve  the low 
rate of capture (14-19%) (Suesskind et al., 2011; Ulmer et al., 2008). Furthermore, there 
are several other markers that may be useful (Table 1) in the immunomagnetic capture 
of UM CTCs due to their common expression in either cutaneous melanoma or UM.  
2.5.2 Genetic Features of Circulating Tumour Cells 
CTCs may constitute a source of tumour DNA reflecting the genetic landscape within the 
primary tumour (Heitzer et al., 2013a) and have recently been used to detect tumour 
specific mutations (Gasch et al., 2013; Heitzer et al., 2013a; Maheswaran et al., 2008). 
Single colorectal cancer CTCs were detected using an immunomagnetic method, then 
isolated by micromanipulation and amplified via whole genome amplification (WGA). 
The resultant WGA-DNA was sequenced and detectable mutations in Kirsten Rat 
Sarcoma Viral Oncogene Homolog (KRAS) and Phosphatidylinositol-4,5-Bisphosphate 
3-Kinase Catalytic Subunit Alpha (PIK3CA) were identified in metastatic cases (Gasch 
et al., 2013). In a follow-up study, WGA-DNA of single CTCs was analysed for tumour 
specific copy number variations (analysed by comparative genomic hybridisation (CGH)) 
and driver mutations, analysed by ultra-deep sequencing, presently identified in both the 
primary tumour and metastases. In addition, mutations found initially only in CTCs were 
also discovered at subclonal level in both the primary tumour and metastases (Heitzer et 
al., 2013a). Furthermore, in this same study it was shown that the average copy number 
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profiles from 10 captured CTCs showed similarities between the solid tumours and the 
CTC copy numbers (Heitzer et al., 2013a). 
Similar to the above, Ulmer et al. (2004) used MCSP to immunomagnetically capture 
CTCs from patients with cutaneous or uveal melanomas that had either localised or 
metastatic disease. A single UM CTC was isolated by micromanipulation and analysed 
by CGH.  Genetic abnormalities associated with poor prognosis in UM such as 
monosomy of chromosome 3 was detected in this cell. More recently, CTCs were isolated 
from patients using gp100 and CD63 followed by fluorescence in-situ hybridisation to 
detect chromosome 3 copy numbers. It was found that in 10/11 cases tested, the status of 
chromosome 3 correlated with its status in the primary tumour (Tura et al., 2016).  
Adding to the evidence that UM CTCs can act as a source of genetic material, it has been 
shown that genetic mutations within the primary are also present within metastases (Singh 
et al., 2009; Trolet et al., 2009); UM is a relatively stable malignancy (Cross et al., 2003), 
and as UM spreads by haematogenous dissemination (Tulley et al., 2004), CTCs released 
into the blood may harbour these mutations. As the genotype of UM can accurately 
predict the metastatic propensity of the primary tumour, detection and isolation of single 
CTCs could allow for an accessible and accurate method of prognostication. 
In addition to CTCs, circulating tumour DNA (ctDNA) has been used to provide another 
means of non-invasive analysis of tumour characteristics (Bettegowda et al., 2014; Bidard 
et al., 2014; Dawson et al., 2013). These ctDNA manifests as a result of apoptosis and 
necrosis of tumour tissue (Alix-Panabieres et al., 2012), and should therefore encapsulate 
the genetic landscape of all tumours within the body. Due to a high proportion of recurrent 
hot spot mutations in GNAQ, GNA11, PLCβ4, and CYSLTR2, detection of ctDNA is 
easily possible in UM. Bidard et al., (2014) detected ctDNA in 84% UM patients with 
metastatic disease, with ctDNA levels correlating with miliary hepatic metastasis, 
metastasis volume and number of CTCs.  Detectable ctDNA correlated with a poor 
prognosis (Bidard et al., 2014). However, the presence of ctDNA has not been yet 
evaluated in patients with localised UM. 
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3.0 Theoretical Framework 
Given that approximately 50% of patients diagnosed with localised UM develop 
incurable metastatic disease (Jovanovic et al., 2013) and within two years, 92% of patients 
with detectable metastasis will die (COMS-26, 2005). It is therefore important to 
determine early whether a patient will develop metastatic disease. Armed with such 
knowledge, clinicians can evaluate adjuvant therapies at an earlier stage to prevent the 
development of metastases. 
 Histopathological features combined with molecular analysis are now able to accurately 
predict prognosis. Research into the expression of genes in UM has revealed two distinct 
classes with distinct/specific genetic aberrations and these are significantly associated 
with metastatic propensity (Figure 13). Current molecular prognostic testing, however, 
requires sampling of the primary tumour and due to the inherent complications of direct 
biopsy of the eye, such as vitreous haemorrhage, retinal detachment, and permanent 
blindness (Pereira et al., 2013), an alternative source of tumour DNA for genetic analysis 
is desirable. In this regard, CTCs may provide a suitable sample with which to assess the 
genetic characteristics of the tumour for determining the metastatic potential of the 
patient’s UM. However, the methods to carry out this analysis have yet to be rigorously 
evaluated. 
 
Figure 13: Key Genetic Events in Uveal Melanoma Tumourigenesis. Diagram 
displaying the bifurcated progression pathway and a review of the key events in UM 
tumour formation and metastasis described on the literature review. 
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3.1 Hypothesis 
CTCs are a suitable source of tumour DNA for the analysis of genetic markers of 
metastatic propensity in patients with UM. 
3.2 Aims 
The overall aim of this project is to refine and evaluate methods for analysing genetic 
characteristics that predict metastatic propensity using CTCs from patients with UM. 
Aim 1: To refine and evaluate methods for multi-marker immunomagnetic capture 
of UM CTCs. 
Aim 2: To develop methodologies for the detection of genetic markers of metastatic 
propensity using single UM cells. 
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Abstract 
Despite excellent local control of the primary tumour approximately 50% of uveal 
melanoma (UM) patients will develop incurable metastatic disease. The stratification of 
UM patients into groups with better or worse prognosis is based on clinicopathological 
and molecular features and is critical for both patient management and for directing 
patients towards clinical trials. However, the classification of tumours is constrained by 
the invasiveness of the biopsy procedure and the limited availability of tissues when 
enucleation is not performed. Here we evaluate the feasibility of using circulating tumour 
DNA (ctDNA) and circulating tumour cells (CTCs) for molecular characterisation of UM 
in patients with localised disease. ctDNA was quantified using droplet digital PCR for 
detection of GNAQ and GNA11 Q209L mutations. Only 19% (5/27) of cases had 
detectable ctDNA. CTCs were immunocaptured from the blood of 23 primary UM 
patients by targeting the melanoma-associated chondroitin sulphate proteoglycan 
(MCSP). This resulted in the isolation of 1-37 CTCs from 15 (65%) patients, an 
inadequate efficiency for diagnostic use. As previous studies of cutaneous melanomas 
had indicated greater capture rates by targeting multiple rather than single markers, the 
expression of uveal and cutaneous melanoma specific markers was examined in UM 
primary tumours and cell lines. We found heterogeneous expression of common markers 
used for capturing CTCs in the tissue microarray (TMA) and cell lines. Markers such as 
MCSP, MCAM, or surface gp100 were heterogeneously expressed at a moderate to high 
level. In contrast 5HT2B and ABCB5 showed higher expression in tissue than in cell lines 
and MCSP was absent in the TMA but present in cell lines. This indicates that due to the 
heterogeneous nature primary UM, targeting of multiple surface markers and cytoplasmic 
markers would improve capture and detection of CTCs in patients. Immunomagnetic 
capture of UM cells using MCAM, MCSP and surface gp100 (BETEB) provided high 
recovery rates of UM cells. These findings suggest that combinations of antibodies would 
increase the efficacy of CTC capture in UM patients, allowing for molecular analysis to 
derive critical prognostic information. 
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Introduction 
Uveal melanoma (UM) is the most common intraocular malignancy and the leading cause 
of death due to primary intraocular disease in adults (McLaughlin et al., 2005). Despite 
successful control of the primary tumour, incurable metastatic disease will ultimately 
develop in up to 50% of patients (Blum et al., 2016). Extensive analysis of primary UMs 
has defined molecular features of the tumour cells that predict, with a high degree of 
accuracy, a patient’s risk for development of metastases. Biomarkers of poor prognosis 
include histopathological features of the tumour, loss of chromosome 3, gain in 
chromosome 6p and 8q (Damato et al., 2010), as well as the differential expression of 
marker genes panels that include well-characterised cancer-associated factors such as 
CDH1 (epithelial cadherin; E-cadherin), 5HT2B (5-hydroxytryptamine (serotonin) 
receptor 2B) and EIF1B (eukaryotic translation initiation factor 1B) (Harbour et al., 
2013). Although distinct biomarker profiles have been validated for personalised patient 
management, invasive surgical procedures with significant risk of sight threatening 
complications are required in order to obtain sufficient tumour tissue for molecular 
analysis (Pereira et al., 2013). Routine implementation of less invasive strategies would 
enable early detection of metastasis and/or implementation of pre-emptive treatment 
strategies.  
Given that metastasis in UM arises from haematogenous dissemination, investigation of 
circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA) could provide a 
unique opportunity for genetic analysis of the patient’s tumour through a simple and safe 
blood test.  The high proportion of recurrent hot spot mutations in GNAQ and GNA11 
allows the detection of ctDNA in UM by droplet digital PCR (Versluis et al., 2015). 
Bidard et al. (2014), detected ctDNA in 84% UM patients with metastatic disease, with 
ctDNA levels correlating with miliary hepatic metastasis, metastasis volume and number 
of CTCs.  Detectable ctDNA correlated with a poor prognosis (Bidard et al., 2014). 
However, the presence of ctDNA is yet to be evaluated in patients with localised UM. On 
the other hand, circulating tumour cells (CTCs) have been previously detected early stage 
UM (Suesskind et al., 2011; Ulmer et al., 2008). CTCs have shown to constitute a source 
of tumour DNA that reflects the genetic landscape of the primary tumour (Gasch et al., 
2013; Heitzer et al., 2013a; Maheswaran et al., 2008). Thus, it would be possible that 
CTCs can be used to detect tumour specific mutations and chromosomal copy number 
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variations that predict the risk of metastasis for individual UM patients. To achieve this, 
CTCs need to be efficiently isolated in early stage UM cases. 
Current methods for isolating UM CTCs involve immunomagnetic capture and size based 
filtration, however the well-documented heterogeneous nature of UM cells is likely to 
complicate the successful isolation of CTCs from all patients. Immunomagnetic capture 
of UM CTCs by targeting the melanoma-associated chondroitin sulphate proteoglycan 
(MCSP (also known as CSPG4, NG2)) protein was shown to successfully detect CTCs in 
patients with primary disease, detecting CTCs in 19% (1-5 CTCs, median = 2.5 CTCs, 
per 50 mL of whole blood) (Ulmer et al., 2008) and 14% (1-8 CTCs, median = 1, per 50 
mL of whole blood) of patients (Suesskind et al., 2011). Bidard et al. detected UM CTCs 
in only 30% of patients with metastatic disease using the CellSearch system (Janssen 
Diagnostics) which targets the melanoma marker MCAM (melanoma cell adhesion 
molecule) and stains for MCSP (Bidard et al., 2014). However, a method using dual 
marker enrichment protocol targeting CD63 (NKI/C3) and glycoprotein 100 (gp100, 
NKI/BETEB), allowed for the detection of CTCs in 94% of patients with primary UM 
(Tura et al., 2014). Thus, a multi-marker approach may be key to enriching the capture of 
CTCs from the majority, if not all, UM patients. In fact, our previous study in metastatic 
melanoma showed that targeting multiple melanoma specific membrane proteins resulted 
in the enrichment of a larger number of CTCs (Freeman et al., 2012).  
Here we initially evaluated the blood of primary UM patients for both: the number of 
CTCs immunomagnetically captured using a single marker (MCSP) and the level of 
plasma ctDNA. To enable greater efficacy and accuracy of capture of CTCs from UM 
patients, we then systematically analysed the expression of several markers in a primary 
UM tumour microarray and in five UM cell lines. Furthermore, we tested these markers 
alone and in combination for their capacity to immunomagnetically capture UM cells 
spiked into peripheral blood. 
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Materials and Methods 
Patients  
UM patients from the Lions Eye Institute and Royal Perth Hospital, Perth, Western 
Australia were enrolled in the study between March 2014 and August 2016. UM was 
diagnosed by clinical and ultrasound examination performed by a specialist 
ophthalmologist to evaluate the size and location of the intraocular tumour including the 
presence of ciliary body involvement. Written informed consent was obtained from all 
patients under approved Human Research Ethics Committee protocols from Edith Cowan 
University (No. 11543) and Sir Charles Gardner Hospital (No. 2013-246), Western 
Australia.  Peripheral blood samples were taken prior to radiation plaque insertion or 
enucleation. For CTC quantification, blood was collected in Vacutainer K2 EDTA tubes 
(BD Biosciences), stored at 4°C, and processed within 24 hours. Plasma was isolated by 
double centrifugation at 1600g for 10 min and stored at -80°C. 
Antibody-Bead Coupling 
Antibodies (BD Biosciences, Table S1) were covalently bound to magnetic beads using 
a Dynabead Antibody Coupling Kit (Invitrogen) following manufacturer’s instructions. 
10µg of antibody was used per mg of Dynabeads. 
Circulating Tumour Cell Capture and Quantification  
Peripheral blood mononuclear cells (PBMCs) were isolated from blood by density 
gradient centrifugation over Ficoll-Paque (GE Healthcare) and resuspended in 1mL 
MACS buffer (0.5% bovine serum albumin (BSA), 2mM EDTA in PBS, pH 7.2) prior to 
the addition of 5µL of MCSP coated immunomagnetic beads. Cells and beads were 
incubated at 4°C for one hour with rotation. Using a DynaMag-2 magnet (Life 
Technologies), bead-captured cells were washed 3 times with MACS buffer, and then 
fixed with 4% paraformaldehyde for 10 minutes at room temperature (RT). Cells were 
washed once in PBS, incubated in PBS containing 10% normal donkey serum (NDS), 1% 
BSA, and 0.2% Triton-X100 (TX-100) for 15 minutes then incubated for 1 hour at RT 
with anti-MART1/gp100/S100β and with anti-CD45-PE antibodies diluted in PBS/1% 
NDS/1% BSA/0.1% TX-100. After incubation, cells were washed in PBS/1% BSA/0.1% 
TX-100, and incubated in 1:500 donkey anti-rabbit Alexa Fluor IgG 488 (Abcam) for 30 
minutes at RT and placed on a magnet for 2 minutes. The resulting pellets were washed 
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3 times with PBS/1%BSA/0.1%TX-100, resuspended in PBS, then mounted using 
Prolong Gold Anti-Fade reagent with DAPI (Life Technologies). Slides were stored at 
4°C, visualised and scanned using the Eclipse Ti-E inverted fluorescent microscope 
(Nikon®). Stained cells were analysed using the NIS-Elements Analysis software, 
version 4.2 (Nikon®, Japan). CTCs were defined as nucleated cells (DAPI positive) that 
were positively stained for gp100, MART1 and S100β, and negatively stained for CD45. 
Circulating Tumour DNA Quantification   
Cell free DNA (cfDNA) was extracted from 1-5 mL of plasma using a QIAamp 
Circulating Nucleic Acid kit (Qiagen) according to the manufacturer’s instructions and 
stored at -80°C. ctDNA was quantified using droplet digital PCR using PrimePCR ddPCR 
Mutation Assays (BioRad) for GNAQ Q209L and GNA11 Q209L. These assays are also 
able to detect GNAQ/GNA11 Q209P mutations (Versluis et al., 2015). Droplets were 
generated using an Automated Droplet Generator (BioRad), amplified using a C1000 
Touch Thermal Cycler (BioRad) and analysed using a QX200 system (Bio-Rad). A 
mutation-positive control, a healthy (wild-type) control and a no template control were 
included in each run.  QuantaSoft version 1.6.6 analysis software (Bio-Rad) was used for 
data acquisition and analysis. Only tests providing more than 10,000 droplets were used 
for analysis. The number of copies of mutated DNA per 20 µL reaction was extrapolated 
to calculate copies per mL. Samples derived from the plasma of healthy individuals were 
used to determine the specificity of each assay (Table S2). 
UM Specimens and Tissue Microarray Construction  
Formalin-fixed, paraffin-embedded (FFPE) blocks from 10 primary choroidal UM treated 
by enucleation between 2012 -2014 at Royal Perth Hospital, Western Australia, were used 
to construct the tissue microarray (TMA). A waiver of consent was obtained for all 
archived tissue blocks under approved Human Research Ethics Committee protocols from 
Edith Cowan University (No. 12593), Western Australia.  The TMA was generated using 
the TMA Master Tissue Microarrayer (3DHistech). Duplicate (8 patients) and 
quadruplicate (2 patients) 1 mm cores were taken from areas with high tumour content 
designated by a pathologist. Non-UM control tissues were obtained from FFPE cutaneous 
melanoma and normal tonsil, liver, lung, breast, and skin.  
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Multiplex Ligation-Dependant Probe Amplification for Detection of Copy Number 
Variants 
To determine chromosomal copy number variations (CNVs), DNA was extracted from 
FFPE UM specimens by proteinase K digestion and purification through spin columns 
(Qiagen). For MLPA analysis, 50-120ng DNA was analysed using a SALSA P027-C1 
UM probemix kit according to the manufacturer’s instructions (MRC Holland, 
Amsterdam, Netherlands). Samples were separated by capillary electrophoresis on an 
ABI-3730XL DNA Analyzer (Applied Biosystems) and analysed using Coffalyser 
software (MRC Holland) to determine copy number changes on chromosomes 1p, 3, 6 
and 8. 
Immunohistochemistry 
Immunohistochemistry was performed on 4 µm sections cut from the FFPE TMA block. 
Sections were depariffinised in xylene followed by rehydration in graded ethanols for 3 
minutes each then washed in running dH2O for 1 minute. Antigen retrieval was performed 
in an 850W microwave oven for 15 minutes on 100% power in sodium citrate pH 6.0 
buffer (gp100, MART1) or EDTA pH 8.0 buffer (MCAM, Nestin, ABCB5, RANK, 
5HT2B, S100β, MCSP). Slides were then cooled for 8 minutes in running dH2O, 
permeabilised in 0.025% TX-100 in TBS (50 mM Tris-Cl, 150 mM NaCl, pH 7.6) for 20 
minutes then immunostained using an EnVision+ Dual Link System-HRP (DAB+) 
(Dako) according to the manufacturer’s instructions. Briefly, slides were incubated with 
Endogenous Enzyme Block for 10 minutes, rinsed 3 times for 5 minutes in TBS/0.025% 
TX-100 then incubated overnight at 4°C with primary antibody diluted in TBS/1% BSA 
(Table S1). The following day, slides were washed 5 times for 5 minutes in TBS/0.025% 
TX-100, incubated with Labelled Polymer-HRP for 30 minutes, rinsed 3 times for 5 
minutes in TBS/0.025% TX-100, incubated for 5 minutes with Substrate Chromogen, and 
then rinsed in dH2O. Slides were counterstained with Harris hematoxylin (Sigma) for 8 
minutes, rinsed in running dH2O for 1 minute, blued in 0.2% ammonia water for 2 minutes 
and mounted with ProLong Gold Antifade Mountant (Thermo Fisher Scientific). 
Immunostaining for each marker was evaluated by two independent observers as follows: 
negative (0), weak (1), moderate (2) or strong (3). 
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Cell lines 
The cell lines MM28, MP38, MP46, MP65 and MP41 exhibiting genetic profiles typical 
of clinical UM were kindly donated by Prof Roman-Roman from the Institut Curie, 
France (Amirouchene-Angelozzi et al., 2014). Cells were cultured in RPMI 1640 medium 
supplemented with 20% foetal bovine serum (FBS) at 37°C in a humidified 5% CO2 
incubator. 
Flow Cytometry 
MM28, MP38, MP41, MP46, and MP65 cells were harvested by incubation in 5mM 
EDTA in RPMI 1640, resuspended then washed 3 times in FACS buffer (PBS with 0.1% 
BSA, 25mM HEPES, 1mM EDTA, pH 7.0), incubated with primary antibody (Table S1) 
for 30 minutes at 4°C and washed 3 times in FACS buffer. Cells were then incubated with 
secondary antibody Alexa Fluor 488 conjugated donkey anti-rabbit or anti-mouse Ig 
(Abcam) diluted 1:500 in FACS buffer for 15 minutes at RT and washed 3 times in FACS 
buffer prior to flow cytometric analysis on a Gallios Flow Cytometer (Beckman Coulter) 
and analysed with the Kaluza software package (Beckman Coulter). 
Immunocytochemistry 
UM cell lines were fixed in PBS/4% paraformaldehyde for 10 minutes, washed 3 times 
for 5 minutes in PBS, blocked in PBS/1% BSA/10% NDS, then incubated overnight at 
4°C with primary antibody (Table S1) diluted in PBS/1% BSA/1% NDS and washed 5 
times for 5 minutes in PBS. Cells were then incubated for 1 hour at RT with Alexa Fluor 
488 conjugated donkey anti-rabbit or anti-mouse IgG (Abcam, Table S1) diluted 1:500 
in PBS/1% BSA/1% NDS, washed 3 times for 5 minutes in PBS, mounted with ProLong 
Gold Antifade Mountant plus DAPI (Thermo Fisher Scientific) and analysed using an 
Olympus BX51 microscope equipped with an Olympus DP71 camera and DP Manager 
Software. 
Retrieval of UM Cells Spiked into Peripheral Blood Mononuclear Cells 
UM cell lines were labelled with 2 µM CellTracker Red CMTPX Dye (Life 
Technologies) by incubation at 37°C for 30 mins and harvested using 5 mM EDTA/RPMI 
1640 (Gibco). Only cells with more than 90% viability were used. Following harvesting, 
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50 cells (BETEB, MCAM, and MCSP) were manually captured and spiked into PBMCs, 
equivalent to 4 mL blood, resuspended in MACS buffer. For 5HT2B and ABCB5 capture 
1000 cells were spiked by dilution. 1 µL of antibody-bead conjugate was added to the 
cells and incubated for 1 hour at 4°C with gentle rotation. Enriched cells were then placed 
on a DynaMag-2 magnet (Invitrogen), washed 3 times with MACS buffer, fixed in 4% 
PFA/PBS, washed once in PBS, and mounted using Prolong Gold with DAPI Antifade 
Mounting Medium (Invitrogen). Slides were left for 24 hrs before scanning the entire area 
for DAPI/CMTPX positivity. Cells that had a blue labelled nucleus, with red cytoplasm 
were determined to be spiked UM cells whereas blue labelled nuclei without red 
cytoplasm were classified as WBCs. 
Results 
Quantification of Circulating Tumour DNA (ctDNA) and Circulating Tumour Cells 
(CTCs) in Patients with Localised UM Patients 
To determine whether ctDNA was detectable in patients with localised UM, plasma 
samples from 27 patients (clinical characteristics detailed in Table 1) were analysed for 
the presence of the UM associated mutations GNAQ Q209L/P and GNA11 Q209L/P. We 
did not gain previous knowledge of the mutational status of patient matched tumours. 
Instead all patient bloods were tested for these mutations as they have been reported to 
occur in approximately 77% of UMs (van Raamsdonk et al., 2010). We detected ctDNA 
in 5 of the 27 patients tested (19%, range 2-28.5 copies), 2 cases had a GNAQ Q209L 
mutation and 3 had the GNA11 Q209L variant. Of note, all five cases with detectable 
ctDNA also had CTCs (Figure 1b). On those with detectable mutations, ctDNA levels 
were associated with tumour size (largest basal/apical diameter) (Figure 1c and d).  
To determine the UM CTC detection rate using a single target, CTCs were isolated from 
blood samples donated by 23 UM patients using immunomagnetic capture targeting 
MCSP. True CTCs were identified in this population by positive staining for 
MART1/gp100/S100β and negative staining for CD45 (Figure 1a). A total of 15 (65%) 
individuals had at least 1 CTC in 8 mL of blood, with a range of 1-37 CTCs detected, 
while 12 (52%) patients had 2 or more detectable CTCs. Only single cells, rather than 
clusters, were detected in all cases. The presence or quantity of CTCs captured using 
MCSP did not correlate with the tumour basal or apical size (Figure e and f).  Among 
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the 10 cases that underwent tumour biopsy no significant difference was found between 
the number of CTCs and monosomy or loss of chromosome 3 in the tumour (Figure 1g).  
Analysis of Marker Expression in primary UM tumours 
Due to our moderate rate of CTC capture in patients with a single marker, MCSP, we 
performed a literature search to determine potential cell surface markers that could be 
used in combination to improve the detection rate and the number of CTCs captured and 
intracellular markers that could improve CTC identification.  
The markers chosen included previously described targets for immunocapture or 
identification of UM CTCs, such MCAM (Bidard et al., 2014), glycoprotein 100 (gp100) 
(Hoashi et al., 2005; Tura et al., 2014; Tura et al., 2016), melanoma antigen recognised 
by T cells 1 (MART1) (Zhang et al., 2013), and S100 calcium binding protein β (S100β) 
(Harpio and Einarsson, 2004). Other molecules selected included 5-hydroxytryptamine 
receptor 2B (5HT2B), a membrane protein previously shown to be upregulated in class 
II UMs (high metastatic risk) (Onken et al., 2004) and liver metastasis (Zhang et al., 
2014). ATP-binding cassette sub-family B member 5 (ABCB5) previously found to be 
enriched in cutaneous melanoma CTCs (Gray et al., 2015a; Schatton et al., 2008), and 
reported to be localised at the leading edge of UMs (Thill et al., 2011), receptor activator 
of nuclear factor κ β (RANK), which is involved in migration and metastasis of cutaneous 
melanoma (Kupas et al., 2011) and found in cutaneous melanoma CTCs (Gray et al., 
2015a), and Nestin, a cancer stem cell marker (Neradil and Veselska, 2015), found 
primarily in non-pigmented cells in UM  (Thill et al., 2011), were also assessed for 
expression in UM tumour tissue. 
Marker expression was assessed in a tumour microarray (detailed clinical characteristics 
Table 2) according to the intensity of immunohistochemistry staining (Figure 2a and b). 
All tumour cores were assessable, with the exception of tumour specimen PUM7, where 
only 3 of 4 cores could be scored. Representative images of positively stained cores for 
each of the markers are shown (Figure 2c). Duplicate cores were generally consistent in 
their staining intensity and the average intensity score per protein was calculated relative 
to the mean intensity score of all tumours that expressed the protein. For most cases, 
where strong staining for an individual marker was observed, that marker was 
homogeneously expressed in the tumour (Figure 2c). An exception was S100β where 
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only a proportion of tumour cells exhibited strong expression, with positively stained cells 
often clustered in small areas (Figure 2c). All tumours expressed gp100 and MART1, 
with an average expression intensity of 1.4±0.4 and 2.5±0.7 respectively (Table 3). Other 
intracellular markers, S100β and Nestin were expressed at similar intensity but in a lower 
proportion of tumours (70% and 60%, respectively). Interestingly, ABCB5 was strongly 
expressed in 90% of tumours (average expression intensity 2.7±0.5). Of note, in addition 
to its well-characterised membranous location (Lutz et al., 2016), ABCB5 was also 
localised within the cytoplasm of UM cells (Figure 2c). Other markers such as 5HT2B 
(1.1±0.2), MCAM (1.6±0.5) and RANK (1.3±0.4) exhibited moderate levels of 
predominantly membrane-associated expression and were expressed in a lower 
proportion of tumour samples (Table 3). Interestingly, 5HT2B and MCAM expression 
coincide in various tumours (PUM5, 6, 10 and 9) and within areas of the tumours (Figure 
2c). Lastly, MCSP was not detected in any of the UM specimens, but was strongly 
expressed in the cutaneous melanomas used as positive controls (Figure 2a). 
Analysis of Marker Expression in Primary and Metastatic Cell Lines 
We further evaluated the expression of marker proteins in cell lines derived from primary 
(MP38, MP41, MP46, and MP65) and metastatic (MM28) UM using flow cytometry and 
immunocytochemistry. Flow cytometric analysis of UM cell lines revealed high levels of 
expression of cell surface gp100 (BETEB), MCAM and MCSP, with differential marker 
expression between cell lines (Figure 3). For example, MCSP, a biomarker commonly 
used to capture CTCs was expressed in all cell lines except for MP41. In contrast, 5HT2B 
and ABCB5 were expressed in only a small proportion of the cells within each cell line, 
apart from MP38, which exhibited low but homogeneous staining for 5HT2B (Figure 3).   
We also assessed, by immunocytochemistry, the expression of intracellular markers 
which can be used for identification of CTCs and found that the melanocyte markers 
gp100 and MART1 were uniformly expressed in all cell lines. Nestin and S100β were 
expressed in a more heterogeneous pattern, with Nestin exhibiting high expression in 
MM28, MP38, and MP41 whilst MP46 and MP65 had medium levels of expression, and 
S100β only expressed in a subset of cells in each cell line (Figure 4). 
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Immunomagnetic Isolation of UM Cell Lines 
To determine if 5HT2B, ABCB5, gp100 (BETEB), MCAM, and MCSP were suitable for 
capturing UM CTCs, we spiked cells into the equivalent of 4 mL of isolated PBMCs. We 
found that immunomagnetic capture and enrichment of UM cells using individual 
markers could capture large proportion of the spiked cells; BETEB 32±2/50 (64%); 
MCAM (51%) and MCSP 33±3/50 (66%) (Figure 5). However, targeting 5HT2B and 
ABCB5 captured a very low per cent of spiked cells 5HT2B 5±1/1000 (0.5%); ABCB5 
3.6±0.5/1000 (0.36%), consistent with the low frequency of positive cells for these 
markers (Figure 3). When all beads were combined a similar level of cell retrieval 
59±9.5/100 (59%) was found when compared to individual beads targeting MCAM, 
BETEB or MCSP (Figure 5).  
Discussion 
Prognostication and routine monitoring of UM patients constitute essential components 
of disease management that are hampered by the limited availability of primary tumour 
tissue, resulting from the preferred use of brachytherapy with sight-conserving surgery, 
and a lack of sensitive validated tests to detect minimal residual disease or early disease 
recurrence. As up to 50% of UM patients will develop metastatic tumours following short 
or very long latency periods (Kujala et al., 2003), the ongoing monitoring of patients 
should ideally involve relatively non-invasive procedures that minimise the high 
cumulative radiation exposure associated with repeated scans. Analysis of CTCs, both to 
stratify UMs into low or high risk categories and to monitor disease recurrence or 
progression potentially fulfils these criteria, pending the development of robust CTC 
capture and test methods. 
As shown in this study, ctDNA is not commonly detectable in blood of patients with 
localised UM. In contrast, most metastatic UM cases we have tested have detectable 
ctDNA (data not shown), consistent with the report by Bidard et al. (Bidard et al., 2014). 
Thus, ctDNA monitoring using sensitive methodologies like ddPCR might be useful for 
early detection of metastatic disease. In addition to GNAQ and GNA11 mutations, other 
‘hotspot’ mutations have been identified in primary UM, such as PLCβ4 D630Y (7%) 
and CYSLTR L129Q (3%) (Johansson et al., 2016; Moore et al., 2016). The inclusion of 
40 
 
 
assays to test for these mutations would increase the utility of ctDNA for monitoring of 
disease burden. 
To enrich for CTCs, a single marker has been used in patients with UM and this has 
typically resulted in low numbers of patients having detectable CTCs. Previous reports 
using MCSP to capture CTCs attained a detection rate of 14-19% in UM patients with 
non-metastatic disease, with 1-5 CTCs detected in 50 mL of blood (Suesskind et al., 2011; 
Ulmer et al., 2008). Although when we used the same single marker (MCSP) to capture 
CTCs, our method of immunomagnetic isolation achieved a slightly higher detection rate 
than previous reports, with 1-37 CTCs detected in 65% of cases, a result that may be 
accounted for by differences in the isolation and detection methods employed, such as 
immunostaining with multiple well expressed melanoma markers, and direct conjugation 
of antibodies to immunomagnetic beads. In other studies, that used different markers to 
capture CTCs, diverse rates of detection have been reported. For example, a study using 
CellSearch (MCAM based capture) achieved a detection rate of 50% in patients with 
non-metastatic disease, with 1-3 CTCs detected in 7.5 mL of blood (Bande et al., 2015). 
More recently, Tura et al., (2014) showed that by targeting multiple markers NKI/C3 and 
NKI/BETEB (CD63 and gp100) a CTC capture rate of 94% was able to be achieved in 
patients with non-metastatic disease, with 1-10 CTCs detected in 10 ml of blood. 
Consistent with these results, our laboratory has previously shown that a multi-marker 
immunomagnetic enrichment protocol captured a higher number of cutaneous melanoma 
CTCs by targeting four markers (Freeman et al., 2012). 
To investigate potential markers for use for CTC capture, a panel comprising, 5HT2B, 
ABCB5, surface-gp100 (BETEB), MCAM, and MCSP was chosen based on the known 
roles of these factors in UM (Bande et al., 2015; Harbour and Chen, 2013; Thill et al., 
2011; Tura et al., 2014; Ulmer et al., 2008). Surprisingly, MCSP, which we and others 
have successfully used to capture CTCs, was not expressed in any of the primary human 
UM tumour specimens although it was strongly expressed in all but one of the UM cell 
lines. Similar results of MCSP variable expression have been previously reported on other 
UM cell lines (Cools-Lartigue et al., 2008). MCSP is highly expressed in cutaneous 
melanomas, and although its expression is not well-characterised in UM, a previous study 
has described its expression in approximately 95% (18/19) of primary UM tumours 
(Campoli et al., 2004; Li et al., 2003). Reasons for the apparent lack of concordance 
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between MCSP immunohistochemistry results and both our successful use of MCSP 
antibodies to capture UM CTCs and the previous report of Li et al. (2003) are unknown. 
However, it is interesting to note that the MCSP antibody clone (9.2.27) used in our CTC 
capture protocol and in the study of Li et al (2003) were identical and differed from the 
antibody clone used for immunohistochemical detection of MCSP.  Another explanation 
for our lack of apparent immunostaining of MCSP in our UM specimens may be due to 
improper storage conditions or length of storage (Ramos-Vara et al., 2014; Xie et al., 
2011). It is unknown the specific effects of these conditions on MCSP. However, we 
should note that other markers were positively stained in the same tumour samples.  
Of the other markers tested, the well-characterised melanoma antigens, MART1 and 
gp100 were expressed in all our UM tumours, supporting previous studies of their 
detection in UM specimens and their potential inclusion in marker panels to capture UM 
CTCs (de Vries et al., 1998). Similarly, S100β was widely expressed but in a lesser 
proportion (70%) of our UM specimens, while MCAM, which was previously reported 
to be expressed in all of a cohort of 35 specimens (Beutel et al., 2009), was expressed in 
just 4 of our 10 UM specimens. TMAs provide a useful means to evaluate biomarker 
expression, however the relatively small areas of tumour tissue that are able to be 
evaluated in 1mm cores, may result in underestimation of antigen expression if the 
immunohistochemical staining pattern is heterogeneous. For example, heterogeneous 
MCAM expression in UM described in a previous report (Beutel et al., 2009) may have 
contributed to the lower proportion of MCAM-expressing tumours identified in the 
present study. 
A previous study has shown that 5HT2B expression is strongly associated with class II 
UM (Onken et al., 2010) and that its expression is significantly upregulated in UM liver 
metastases (Zhang et al., 2014). Although the role of 5HT2B in metastatic progression of 
UM or promotion of metastatic tumour growth is unknown, inclusion of 5HT2B in 
biomarker panels for CTC isolation may facilitate capture of class II UM cells.  
An interesting finding was that ABCB5 was expressed at elevated levels in a high 
proportion (90%) of UM specimens in a predominantly cytoplasmic localisation. This 
contrasts with the sporadic expression of ABCB5 in cutaneous melanoma tumours (Frank 
et al., 2005; Gray et al., 2015a). ABCB5, is a cancer stem cell marker (Schatton et al., 
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2008) over-expressed in cutaneous melanoma CTCs (Gray et al., 2015a; Ma et al., 2010). 
As class II UM significantly correlates with the gene expression profiles of primitive 
ectodermal and neural stem cells (Chang et al., 2008), use of ABCB5 in biomarker panels 
to detect UM CTCs may select for cells with an increased propensity for metastasis 
development. 
Biomarker expression was also examined in UM cell lines, which carry chromosomal 
losses and gains typical of human UM specimens (Aalto et al., 2001; Damato et al., 2010). 
Several of the markers, notably MCAM, MCSP and gp100 (BETEB) were expressed in 
most UM cell lines and in the large majority of cells in those cell lines. On the other hand, 
5HT2B and ABCB5, which was highly expressed in human UM tissue, was weakly and 
sporadically expressed in the UM cell lines analysed. Discordance on antigen expression 
between tumour tissue and cell lines could be attributed to environmental differences, and 
selection or adaptation to in vitro growing conditions (Kamalidehghan et al., 2012).  
5HT2B, ABCB5, surface gp100 (BETEB), MCAM, and MCSP were also tested for their 
ability to isolate spiked UM cell line cells into PBMCs. We found that BETEB, MCAM, 
and MCSP individually retrieved ~60% of UM of spiked cells, while 5HT2B and ABCB5 
only managed to retrieve an extremely low number (>1%) of cells. This may be due to a 
combination of factors such as low expression level on UM cells or the affinity of 
antibodies used. However, both markers, although capturing only a small fraction of the 
spiked cells, had little non-specific binding to PBMCs. When each marker was combined, 
the retrieval rate was similar to the capture rates of BETEB, MCAM, and MCSP 
individually, which may indicate that as cell lines express high levels of each marker, the 
difference in binding capacity is minimal. The benefit of multiple markers is targeting the 
wide phenotypic differences in patients, where if for example, a patient lacks MCSP 
expression then the remaining markers will continue to ensure CTCs are isolated in these 
patients. Future studies will determine the detection rate yield by using this marker 
combination to capture CTCs in localised UM patients. 
Previous reports have identified that the numbers of CTCs found in patients with localised 
UM do not appear to correlate with prognosis or survival outcomes (Suesskind et al., 
2011; Tura et al., 2014). Similarly, CTC numbers did not correlate with known tissue 
prognostic markers, such as monosomy of chromosome 3 and tumour size in the small 
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number of cases in the present study. Therefore, our aim is not to enumerate CTCs as 
prognostic marker, but to capture CTCs in most patients to provide sufficient cells to 
analyse the genetics of the parental tumour. CTCs as a liquid biopsy may present an 
alternative source of tumour genetic material able to be used to investigate markers of 
patient prognosis, and therefore attempting to capture CTCs in almost all patients is 
worthy of investigation. In this regard, CTCs have been shown to constitute a source of 
tumour genetic material which represents that within the primary tumour (Heitzer et al., 
2013a). Tura et al. (2016) showed that chromosome 3 loss, a marker of poor prognosis 
could be determined by fluorescence in-situ hybridization in single CTCs and that these 
results matched the primary tumour in 10/11 cases.  
In summary, the inaccessibility of primary UM and the strong likelihood of metastatic 
progression of the disease following only local control of tumours, presents major 
challenges for pathology in the provision of prognostic marker profiles and for monitoring 
of progression of the disease. These issues may be overcome using liquid biopsies to 
analyse CTCs and ctDNA, however optimisation of methods will be required to allow 
findings to be translated into clinical practice. A necessary first step in this process is the 
determination and characterisation of biomarker panels for CTC recognition, with the 
present study identifying membrane biomarkers that are widely expressed in UM and 
which may be combined to maximize CTC capture in UM patients. 
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Table 1: Clinical, Genotypic, and Histological Characteristics of Patients 
Undergoing Circulating Tumour Cell Capture 
Patient 
Number 
Age 
(yrs) 
Sex 
(M/F) 
CTC 
Count 
ctDNA 
Copies 
ctDNA 
Mutation Eye Location 
Cell 
Morphology 
(Callendar 
Classification) 
Genetic 
Features 
Tumour 
Size 
(Apex) 
(mm) 
Largest 
Basal 
Tumour 
Diameter 
(mm) 
185 70 F 0 0 - Left Choroid Spindle Monosomy 3 8.3 10 
187 78 M 1 0 - Right Choroid - - 15 20 
198 54 F - 0 - Right Choroid - Monosomy 3 2.5 8 
211 52 F 2 0 - Left  Choroid - Disomy 3 4 12 
210 57 M 3 0 - Right Ciliary Body - - 12.5 18 
212 59 M 37 6 GNAQ Q209L Right Choroid - 
Normal 
chromosome 
1p; disomy 3; 
borderline 
loss 6p; 
borderline 
loss 8 
6 10 
214 52 M 1 0 - Right Choroid - - 3.7 11.8 
220 64 M 5 28.5 GNA11 Q209L Left Choroid - 
Monosomy 3; 
L8q 11 17 
243 74 F - 0 - Left Choroid - - 4 10.7 
242 59 F 4 6 GNAQ Q209L Left Choroid - - 7 12.9 
263 57 F 0 0 - Right Choroid  Spindle B L3; G6p; G6q 10.5 9 
312 50 F 22 0 - Right Choroid  Spindle B - 12 12 
316 57 M 10 0 - Right Choroid - - 2.8 7 
317 64 M 1 2.2 GNA11 Q209L Left Choroid - - 7.6 5.9 
322 48 F 8 0 - Left Choroid - 
Normal 
chromosome 
1p; disomy 3; 
gain in 6p; 
gain in 8q 
2.5 10 
321 61 M 0 0 - Right Choroid  Spindle B - 6.6 12 
340 62 F 2 0 - Right Choroid - - 5.6 8 
354 43 F 6 0 - Right Choroid - - 4.5 10 
385 74 F 0 0 - Left Choroid Mixed 
L1p; 
Monosomy 3; 
G8q 
4 20 
386 63 M 0 0 - Right Choroid - - 6.4 11.5 
400 62 F 0 0 - Left Choroid - Disomy 3 4.87 8 
413 63 M - 0 - Left Ciliary Body Spindle B Monosomy 3 9.8 15 
414 51 F 0 0 - Right Choroid - - 2.8 8 
445 35 M 7 2 GNA11 Q209L Right Choroid - Disomy 3 2 5 
451 79 F 2 0 - Right Choroid - - 3.8 8.5 
481 74 M - 0 - Left Choroid - - 9.2 13 
503 64 M 0 0 - Right Choroid Spindle 
Unclassifiable 
3p with a 
normal 3q; 
G6p. 
6.5 12 
Dash (-) where data was unavailable. 
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Table 2: Clinical, Genotypic, and Histological Characteristics of Patient Tissue Samples Used on the Tissue Micro Array 
ID Age
* 
Cell 
Morphology 
(Callender) 
TMA Cell 
Morphology 
(Callender) 
Tumour Size 
Basal x Height 
Location Metastatic 
Disease: Interval 
Time (Months) 
MLPA 
PUM1 38 
Mixed 
(Predominantly 
spindle) 
Mixed 12 x 9 mm Left choroidal No: 51 No convincing evidence of chromosomal loss or gain** 
PUM2 51 Mixed Spindle / Mixed 12 x 8 mm Right choroidal Yes: 18 loss 3p, 3q, gain 8q 
PUM3 65 Mixed Epithelioid / Mixed 10 x 6 mm Left choroidal Yes:  33 loss 3p, gain 8q 
PUM4 47 Mixed Epithelioid / Mixed 11 x 12 mm Right choroidal Yes:  -3 loss 3p, 3q, gain 8q 
PUM5 59 Mixed Spindle / Mixed 9 x 4 mm Right choroidal No: 42 8q gain 
PUM6 31 
Mixed 
(epithelioid 
cells <10%) 
Epithelioid / 
Mixed 15 x 12 mm Left choroidal Yes: 12 8q gain, some evidence of 3p loss, but not strong 
PUM7 42 Spindle B Spindle 16 x 9 mm Left choroidal Unknown No convincing evidence of chromosomal loss or gain 
PUM8 80 Mixed Spindle 11 x 12 mm Left choroidal Unknown loss 1p, 3p, 3q, gain 8q 
PUM9 59 Mixed Epithelioid / Mixed 14 x 8 mm Right choroidal Yes: 3 loss 3p, 3q, gain 8q 
PUM10 79 Mixed Epithelioid 20 x 15 mm Right choroidal No: 19 No convincing evidence of chromosomal loss or gain** 
 
* Age at enucleation 
** Poorer quality DNA
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Table 3: Average Marker Intensity Score    
Average Marker Intensity Score 
ID ABCB5 MART1 gp100 S100β Nestin 5HT2B MCAM RANK MCSP 
PUM5 3 3 1 2 2 1 1.5 0 0 
PUM6 3 1 2 1.5 0 1 1 0 0 
PUM10 2 3 1 2 2 1 2 2 0 
PUM9 2 2 1 0 2 1.5 2 1 0 
PUM2 3 2.8 1 2 1.5 1 0 0 0 
PUM3 3 2.5 2 1 2 0 0 1 0 
PUM4 2 2.6 1.3 0 0 1 0 1.3 0 
PUM8 3 3 1.5 0 0 0 0 1 0 
PUM7 3 3 1 1 0 0 0 0 0 
PUM1 0 2 2 1 0 0 0 0 0 
0 – not expressed, 1 – low expression, 2 – moderate expression, 3 – high expression 
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Supplementary Table 2: Antibody Information 
Antibody Vendor Product Code Use Dilution 
5HT2B Alomone ASR-035 IHC, ICC, 
FACS 
1:400 (IHC & ICC); 
1:100 (FACS) 
ABCB5 Abcam ab140667 IHC, ICC, 
FACS 
1:100 
BETEB Abcam ab34165 ICC, FACS 1:10 
gp100 Abcam ab137062 IHC, ICC 1:50 
MART1 Abcam ab51061 IHC, ICC, 
FACS 
1:100 (ICC & 
FACS) 1:1000 
(IHC) 
MCAM N/A (donated) CC9 (clone) IHC 1:20 
MCAM BD 
Biosciences 
550314 ICC, FACS 1:100 
MCSP NOVUS NB100-2688 IHC 1:100 
MCSP BD 
Biosciences 
554275 ICC, FACS 1:100 
Nestin Abcam ab18102 IHC, ICC, 
FACS 
1:100 
RANK Abcam  ab13918 IHC 1:100 
S100 Abcam ab4066 IHC, ICC 1:500 
Rabbit Isotype Abcam ab172730 ICC, FACS 1:100 
Mouse Isotype Abcam ab18437 ICC, FACS 1:100 
Anti-Rabbit 
AF488 
Abcam ab150065 ICC, FACS 1:500 
Anti-Mouse 
AF488 
Abcam ab150065 ICC, FACS 1:500 
Immunohistochemistry (IHC), Immunocytochemistry (ICC), Flow Cytometry (FACS) 
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Figure Legends 
Figure 1: Circulating Tumour Cell and Circulating Tumour DNA Quantification in 
Primary Uveal Melanoma. a) Example of a UM CTC found in patient blood. Green 
fluorescence (AF488, Mel) indicates staining with a mix of antibodies against the 
melanoma markers MART1, gp100 and S100β; red fluorescence (PE) indicates CD45 
positivity and blue fluorescence (DAPI) indicates the presence of a nucleus. CTCs were 
identified as green and blue positive and red negative cells. Graphs illustrate CTC count 
vs b) basal median diameter (n=20) or c) tumour size as apical height (n=22). d) 
Comparison of CTC counts in UM patients with and without monosomy in Chr3 (n=8). 
e) Graphs illustrate ctDNA copies/mL vs CTC count in 8 mL of blood (n=23). Blue dots 
indicate the presence of the GNAQ Q209L mutation and red dots indicate the GNA11 
Q209L mutation. Graphs indicate ctDNA copies/mL vs f) basal median diameter (n=23) 
or g) tumour size as apical height (n=25). 
Figure 2: Immunohistochemistry of Uveal Melanoma. TMA staining demonstrating 
a) Examples of how tumours were scored for protein localisation. Left shows strong 
membranous staining and right shows strong cytoplasmic staining. Representative image 
of positive MCSP membranous staining. b) Examples of the criteria used to measure 
staining intensity, from 1 indicating weak staining to 3, the most intense staining. A tissue 
staining negatively by immunohistochemistry (0), is also shown (left), with intrinsic 
melanin pigment. c) Shows a typical positive staining pattern for each of the markers 
analysed.  Dark granular black spots are melanin deposits. All images taken at 200x 
magnification. Scale Bar = 200 μM. 
Figure 3: Expression of Markers in Cell Lines by Flow Cytometry. Flow cytometric 
analysis of primary (MP38, MP41, MP46, and MP65) and metastatic (MM28) cell lines. 
Grey profiles represent negative controls using either rabbit or mouse IgGs depending on 
the primary antibody host 
Figure 4: Immunocytochemical Analysis of Uveal Melanoma Cell Lines. 
Intracellular markers and isotype controls. All images taken at 400x magnification. 
Scale bar denoting 100 µm. 
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Figure 5: Recovery of Spiked Uveal Melanoma Cells from the Mononuclear Blood 
Cell Fraction. 50 cells were spiked into PBMC equivalent to 4 ml of blood. MP38 cells 
were used to test beads conjugated to antibodies targeting 5HT2B, MP41 were used for 
BETEB and MCAM, MP46 were used for ABCB5 and all beads, and MP65 cells were 
used for MCSP. Data represent the mean ± SD of three independent experiments.
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Abstract 
Metastatic risk can be easily defined by mutations in chromosomes 1, 3, 6, and 8 in uveal 
melanoma (UM). Previous research has indicated that circulating tumour cells (CTCs) 
are detectable in virtually all patients, irrespective of the propensity of their tumour to 
metastasise. Herein we tested the ability to accurately determine copy number alterations 
after isolation and detection of single CTCs. We found that immunomagnetic enrichment, 
fixation, permeabilisation, and immunostaining caused no significant alteration to CNV 
detected within single UM cells after whole genome amplification using PicoPlex whole 
genome amplification kit followed by low-pass whole genome sequencing (WGS) using 
the Ion Torrent PGM system. Once optimised, we validated then used this protocol to 
detect a gain of chromosome 8 in a single patient with UM, a classically poor prognostic 
feature. Therefore, we show here that CTCs offer a non-invasive method to acquire 
tumour genetic material with which to assess UM patient prognosis.  
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Introduction 
Uveal melanoma (UM) has a strong propensity to metastasize, with approximately 50% 
of all patients developing incurable metastatic disease. Patients at a high metastatic risk 
can be identified by genetic analysis of the primary tumour by gene expression analysis 
(Onken et al., 2010), detection of distinct chromosomal copy number variations (CNV) 
(Damato et al., 2010), or genetic mutations (Harbour and Chao, 2014).  
Although powerful for determining patient metastatic potential and prognosis, these 
molecular tools require the acquisition of tumour material from the eye which can lead to 
several complications, including blindness (Pereira et al., 2013). Fortunately, there may 
be another suitable source of tumour genetic material from which patient prognosis can 
be derived. Circulating tumour cells (CTCs) are cells shed from a tumour and carried 
around the body via the cardiovascular or lymphatic system. CTCs have previously been 
shown to harbour similar genetic profiles to patient primary tumours (Heitzer et al., 
2013a), and can be used to detect tumour specific mutations in other cancers (Gasch et 
al., 2013; Heitzer et al., 2013a; Maheswaran et al., 2008). In UM a single CTC has been 
amplified and analysed by array comparative genomic hybridisation showing 
abnormalities associated with poor prognosis in UM (Ulmer et al., 2004), and more 
recently prognosis has been derived from CTCs in patients using a modified fluorescent 
in-situ hybridisation technique to detect CNVs of chromosome 3. (Tura et al., 2016). 
As the genotype of UM can predict the metastatic propensity of the primary tumour, the 
detection and isolation of single CTCs may allow for an accessible and accurate method 
of prognostication. However, there are several methodological hurdles that need to be 
overcome to produce a cost-effective assay for whole genome CNV analysis. Firstly, the 
processing of patient blood samples to isolate and detect patient CTCs may affect the 
genetic material of the cell. Secondly, as single cells do not harbour enough DNA for any 
meaningful genetic analysis they must undergo whole genome amplification which may 
also lead to discrepancies in the analysis of the genetic profile of the cell. Herein we 
assessed the effects of processing single UM cells (isolation, detection, capture, whole 
genome amplification, and low-pass whole genome sequencing) to determine the viability 
of CTCs as an alternative, less invasive method of accurately predicting patient prognosis.  
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Materials and Methods 
Cell Culture 
The cell lines MP38, MP41, and MP65 exhibiting genetic profiles typical of clinical UM 
were kindly donated by Prof Roman-Roman from the Institut Curie, France 
(Amirouchene-Angelozzi et al., 2014). Cells were cultured in RPMI 1640 medium 
supplemented with 20% foetal bovine serum (FBS), 100 units/mL Penicillin and 100 
μg/mL Streptomycin (Gibco) at 37°C in a humidified 5% CO2 incubator. 
Antibody-Bead Coupling 
CD146 (MCAM, P1H12, BD Biosciences, 550314), melanoma associated chondroitin 
sulphate (MCSP, 9.2.27, BD Biosciences, 554275), and surface gp100 (NKI/BETEB, 
Abcam, ab34165) were covalently bound to magnetic beads using a Dynabead Antibody 
Coupling Kit (Invitrogen) following manufacturer’s instructions. 10µg of antibody was 
used per mg of Dynabeads.  
 
Single Cell Isolation and Processing 
Cell Line: UM cell line cells were incubated in serum-depleted media for 16-18 hours to 
synchronise the cell cycle of all cells (Supplementary Figure 1), then at this point cells 
were harvested using 5mM EDTA in RPMI 1640 media. Three cells were captured and 
subjected to WGA. The rest of the cells were placed into 1 mL MACS buffer and 5 µL 
Dyna-Beads coated with anti- CD146 antibody was added, followed by a 1 hr incubation 
at 4°C on a roller. Cells were then placed on a magnet for 2 minutes, and washed with 
magnetic activated cell sorting buffer (MACS, 0.5% BSA/2mM EDTA/PBS, pH 7.2) 3 
times. Cells were resuspended in 4% paraformaldehyde in PBS for 10 minutes, placed on 
a magnet for 2 minutes and washed in PBS 3 times. Three cells were captured at this point 
and subjected to WGA. The rest of the cells were blocked and permeabilised using 3% 
BSA/10% normal donkey serum/0.2% Triton-X 100/PBS for 15 minutes, washed once in 
1% BSA/0.1% triton-X 100/PBS, and incubated with primary antibody (MART1, gp100, 
S100, CD45) diluted in 1% BSA/0.1% triton-X 100/PBS for 1 hr, followed by incubation 
with secondary antibody donkey anti-rabbit Alexa Fluor 488 (Abcam) and 10 µg/mL 
Hoechst 33342 (Thermo Scientific) for 30 minutes. Cells were washed 3 times in PBS. 
Cell suspension was placed on a glass microscope slide and analysed by fluorescent 
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microscopy. Single cells were picked using the MMI CellEctor (Molecular Machines) 
and placed into 0.2 mL PCR tubes (Eppendorf). 
PBMC: Healthy donor blood was subjected to density gradient centrifugation via Ficoll-
Paque to separate peripheral blood mononuclear cells. After 3 washes in 50 mL PBS cells 
were resuspended in 1mL PBS. Some cells were captured at this point and subjected to 
WGA. The remainder of the cells were processed as described for the UM cell line 
protocol above. 
Whole Genome Amplification 
Whole genome amplification (WGA) was performed using the PicoPlex WGA Kit 
(Rubicon Genomics) and the Repli-G Single Cell Kit (Qiagen) to manufacturer’s 
specifications following isolation of single cells. 1 ng of genomic DNA (gDNA) from a 
healthy donor, and from MP38, MP41, and MP65 cell lines was also amplified. WGA-
DNA was purified using the Qiaquick PCR Purification Kit (Qiagen) and quantified using 
the Qubit dsDNA BR Assay Kit (Invitrogen). Whole Genome Amplified DNA was run 
on the High Sensitivity D1000 ScreenTape Assay (Agilent) to ensure that the majority of 
WGA product centred around 400bp in size. WGA-DNA was also subjected to multiplex 
PCR covering 100, 200, 300, and 400bp amplicons in the GAPDH gene as described 
previously (van Beers et al., 2006). WGA-DNA was regarded as high quality if the 
majority of WGA-DNA fragments were approximately 400bp in size and the multiplex 
PCR produced 4 amplicons. 
Low-Pass Whole Genome Sequencing 
One hundred nanograms of DNA was used to construct 200bp libraries made using the 
Ion Xpress Plus Fragment Library Kit (Life Technologies) and barcoded using the Ion 
Xpress Barcode Adapters 1-96 Kit (Life Technologies). Somatic mutations and CNVs 
were analysed using the Ion Reporter software (Life Technologies). 
Ethics and Patient Blood Samples 
All procedures have been approved by Human Research Ethics Committees at Edith 
Cowan University (No. 11543) and Sir Charles Gardner Hospital (No. 2013-246), and 
Royal Perth Hospital, Western Australia. Patient blood samples were obtained from 
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Royal Perth Hospital, Western Australia. The patient was diagnosed as per guidelines by 
the American Joint Committee on Cancer. Patient blood samples were taken prior to 
commencement of treatment. Blood was drawn by phlebotomists into BD Vacutainer K2 
EDTA tubes (BD Biosciences) and processed within 4 hours.  
Patient Sample Processing 
The patient is a 59-year-old female diagnosed with choroidal UM. Peripheral blood was 
drawn prior to radiation plaque therapy. After harvesting plasma, PBMCs were isolated 
by density gradient centrifugation using Ficoll-Paque (GE Healthcare). Separated PBMCs 
were resuspended in 1mL MACS buffer, and 2µL of Dyna-Beads coated with anti-surface 
gp100, MCAM, and MCSP, was added. Cells were fixed in 4% paraformaldehyde and 
immunostained as described above for UM cell lines, and analysed by fluorescent 
microscopy. Cells that were green (MART1/gp100/S100β positive), not red (CD45 
negative), and had a blue nucleus (Hoechst 33342) were deemed to be CTCs, and cells 
that were red with blue nucleus were classified as PBMCs. Single CTCs and PBMCs were 
captured using the MMI CellEctor (Molecular Machines) and deposited in 0.2 mL PCR 
tubes in 2 µL volumes. Captured cells were whole genome amplified by PicoPlex and 
sequenced as described above in Whole Genome Amplification and Sequencing. 
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Results 
We selected 3 UM cell lines with multiple chromosomal CNVs (Amirouchene-Angelozzi 
et al., 2014), MP38, MP41, and MP65 to evaluate our methodology. Single cells were 
picked and subjected to WGA, i) prior to any processing, ii) after fixation using 
paraformaldehyde, and iii) after permeabilisation and immunostaining. 
Quality Control of Whole Genome Amplified DNA 
To ensure that the WGA produced high quality DNA suitable for accurate CNV analysis, 
WGA-DNA was analysed using TapeStation and multiplex PCR. WGA-DNA was 
determined to be suitable for low-pass WGS if the multiplex PCR produced 4 amplicons 
(Figure 1a) and if the TapeStation showed the majority of WGA-DNA to be 
approximately 400bp in length (Figure 1b). 
Effects of the Whole Genome Amplification Process on Downstream Copy Number 
Variants 
Firstly, we wished to ascertain whether the WGA process itself led to any significant 
biases during sequencing. We sequenced bulk gDNA, 1ng of gDNA subjected to WGA, 
and 3 single cell WGA-DNA products. Here we showed that when compared to the bulk 
gDNA, the gDNA-WGA (PicoPlex only) and single cell WGA-DNA from both PicoPlex 
(Figure 2) and Repli-G (Figure 3) do not differ significantly. Small differences were 
observed, e.g. the lack of a gain in 6p and 14p in MP38 cell 3 (Figure 2a), possibly due 
to the stochastic effect of cell culture. However, Repli-G has more noticeable spread on 
the copy number per bins within the chromosomes, reducing confidence in the CNV call. 
For example, more CNV errors were observed in Repli-G MP41 Cell 2 than in any of the 
PicoPlex analysed cells where the CNVs observed resembled the known values 
(Amirouchene-Angelozzi et al., 2014). Therefore, the process of WGA by PicoPlex 
introduced little bias at a WGS depth of 0.01-0.1x. 
Effects of Cell Processing on Whole Genome Amplification and Copy Number 
Variants 
Next, we wanted to test the effects of processing of cells, for the identification of CTCs 
in patients. To determine these effects, we analysed WGA-DNA of cells that had been 
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fixed, or fixed, permeabilised, and stained using both Repli-G and PicoPlex WGA 
methods. Repli-G did not amplify samples that had been fixed. Compared to the genomic 
DNA (Figure 4a), fixation in 4% paraformaldehyde did not significantly alter the 
PicoPlex WGA-DNA (Figure 4b). However, the full process of fixation, 
permeabilisation, and staining did cause some alterations to the chromosomal CNV, such 
as a gain in the entirety of chromosome 2 and variance in chromosome 12q, however 
these cells continued to correctly display the correct prognostic information, concordant 
with the gDNA alterations found in chromosomes 1, 6, and 8 (Figure 4b-d).  
Copy Number Variations Detected in Patient Samples 
To demonstrate the clinical application of the methodology described, we isolated CTCs 
from a UM patient prior to radiation plaque insertion. We detected one CTC in this patient 
and isolated this for further analysis. We found in a single CTC from this one patient 
(Figure 5), a gain of chromosome 8, a regularly amplified chromosome in poor 
prognostic UM.  
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Discussion 
The majority of UM CTC studies utilise detection and quantification of CTCs to try and 
determine prognosis but have generally found no significance between the levels of CTCs 
and patient prognosis (Suesskind et al., 2011; Tura et al., 2014). We have shown similar 
results in our previous studies (not published). Approximately 50% of patients develop 
metastasis, and most patients have CTCs irrespective of the propensity of their tumour to 
metastasise, indicating the presence of CTCs is not the determining factor in the 
production of metastasis. Therefore, the ability to detect the genomic features in these 
CTCs may offer a greater perspective into patient metastatic risk and prognosis over 
quantification of CTCs. This study illustrates that immunomagnetic capture and detection 
of single UM cells followed by WGA and low-pass WGS (>0.01-0.1X) can accurately 
represent the genomic landscape of the primary tumour.  
The notable differences we found in UM cells that were immunomagnetically captured, 
fixed, permeabilised, and stained prior to amplification with PicoPlex relative to known 
chromosomal arrangements (Amirouchene-Angelozzi et al., 2014), may be partially 
explained by the use of a later passage of MP41 compared to the initial experiments on 
fresh cells, as single PBMCs  consistently retain their balanced karyotype. Thus, PicoPlex 
is a suitable choice of WGA that is able to retain the genetic profile of single cells, and is 
suitable for detection of CNVs associated with prognosis in UM. 
The critical step in the success of using single CTCs as a surrogate for primary tissue to 
determine prognosis, is the choice of WGA kit. Previous studies have assessed the 
limitations and benefits of many different kits (Gawad et al., 2016; Huang et al., 2015; 
Zong et al., 2012), but we found that PicoPlex was able to amplify single cell derived 
DNA with only minor alterations regardless of chemical fixation via covalent cross-
linking.  Moreover,  PicoPlex has an intermediate false positive/negative and high 
uniformity of coverage (Gawad et al., 2016), allowing for greater success in measuring 
CNVs (de Bourcy et al., 2014).  
PicoPlex, when compared to the multiple displacement amplification (MDA) method 
such as Repli-G, produces small (~400bp) fragments. This prevents the use of some probe 
based detection methods for downstream analysis such as ddPCR or Ampliseq kits to 
detect somatic alterations in the amplified DNA as amplification sites may not be covered 
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by previously designed primers whereas detection of SNPs relevant to UM was possible 
in all successful cells amplified using the MDA method (Figure S2). 
Due to the infrequent nature of fine-needle biopsies, comparison between the tumour and 
CTC genotypes was not possible for the single patient assessed here. Future studies would 
be required to confirm the relationship between genetic profile of the primary tumour and 
disseminated CTCs.  However, our single patient CTC displayed a gain of chromosome 
8 which has been regarded as an early event in tumourigenesis of UM (Ehlers et al., 2008; 
Hoglund et al., 2004), and may indicate the dissemination of CTCs is also an early event 
of UM metastasis in this patient.  Tura et al (2016) revealed significant concordance 
between the status of chromosome 3 in the primary tumour and CTCs. Furthermore, 
methods that employ WGA may be able to further stratify patients with class I tumour 
phenotype into the more recently described class Ia or Ib owing to mutations that 
generally segregate into these classes (Field et al., 2016) enabling a finer assessment of 
patient metastatic propensity over the classical class I/II. Additionally, a small portion of 
metastasising UM are disomy 3. WGA-DNA may be useful in determining mutations 
associated with disomy 3 metastatic UM (Lake et al., 2010) or isodisomy 3 via allelic 
frequency. However, this assessment was beyond the scope of this study. 
Previous studies have used array comparative hybridization (Ulmer et al., 2004) or 
fluorescence in-situ hybridisation (FISH) (Tura et al., 2016) to detect changes relevant to 
patient prognosis. We utilised low-pass WGS due to its effectiveness in determining 
chromosomal arm level alterations across the whole genome, whereas aCGH is expensive 
and FISH is limited to a single or a couple of loci, and orientation of cells can cause under- 
or overestimation of changes to CTC genomic profiles. Therefore, the use of low-pass 
WGS as a method of predicting CNV alterations may be more beneficial due to its lower 
cost, higher resolution and the lack of requirement for the correct orientation of CTCs on 
a slide. Nevertheless, WGS for each patient also requires amplification of a WBC as a 
control to properly compare CNVs in each patient, which does raise the cost per patient.  
Currently, the multiplex ligation-dependent probe amplification (MLPA) technique is 
used to assess the copy number status of chromosomes 1p, 3, 6, and 8. The cost of each 
MLPA test is approximately $30 (Australian dollars). Multiple positive controls and 
normal DNA controls need to be run at the same time. Further increases in cost are derived 
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from running only 1-2 samples at a time given the low frequency of the disease and the 
need for a fast turnaround time. Further increases in cost are derived from running only 
1-2 samples at a time given the low frequency of the disease and the need for a 00fast 
turnaround time. The cost of our methodology is higher, at approximately $190 
(Australian dollars) a sample, noting that multiple CTCs are taken per patient, including 
a single PBMC. Although the cost of our methodology is high on a per sample basis, it 
reduces the reliance on a trained surgeon to acquire tissue, prevents any cost if there are 
complications from surgery, reduces morbidity, and provides more information about the 
genotype of the patient. Although beyond the scope of this study, WGA-DNA could 
possibly be used to detect mutations in genes that can stratify patients into more precise 
prognostic categories if required, or can be used to detect isodisomy of chromosomes 
using allelic fraction. 
In summary, our study demonstrates that isolation, WGA, and low-pass WGS harbours 
little artefacts or aberrations and therefore the cells isolated may provide an easier and 
safer alternative ‘liquid biopsy’ of the patient primary tumour. Insights into the genomic 
characteristics of primary tumours provides crucial prognostic information that can be 
used to refer patients to clinical trials, allows more routine monitoring for metastatic 
disease, and provides opportunities for the use of potential adjuvant therapies to prevent 
metastatic disease. 
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Figure Legends 
Figure 1: Quality Control of Whole Genome Amplified DNA. a) 1 and 20 - genomic 
DNA ladder; 1 – positive PCR control; 3-5, 7-9, 11, 13, 15-18 –high quality WGA-DNA; 
6, 10, 14 – poor quality WGA-DNA.; and 19, PCR negative control. New WGA product 
was made to replace the DNA in lanes 6, 10, and 14 to ensure all 4 amplicons were present 
before sequencing. b) Left – High quality WGA-DNA with the majority of fragments 
centred around 400bp in length; right – poor quality WGA-DNA with the majority of 
DNA fragments lower than 400bp in size. 
Figure 2: Effects of PicoPlex Whole Genome Amplification on the Genomic 
Landscape of Uveal Melanoma Cells. UM cell lines MP38, MP41, and MP65 plus a 
healthy donor had gDNA extracted and sequenced along with gDNA amplified using 
PicoPlex and Picoplex WGA-DNA from 3 single cells from the respective cell line / 
donor, a) MP38, b) MP41, c) MP65, and d) a healthy donor. The whole genome amplified 
genomic DNA and individual cells all show concordance with the respective genomic 
DNA. Minor changes to cell line genomic profiles, such as gain in 6p and 14p in MP38 
PicoPlex Cell 3 when compared to the gDNA, may be the result of the stochastic effects 
of cell culture rather than artefacts from the kit. 
Figure 4: Repli-G Whole Genome Amplification on the Genomic Landscape of 
Uveal Melanoma Cells. UM cell line MP41 had genomic DNA extracted and sequenced 
a) along with DNA amplified from single cells b-d) by Repli-G. The DNA product 
produced was sequenced alongside MP41 genomic DNA. Each of the 3 cells displays 
concordance with the sequenced genomic DNA, however the sequenced cells appear to 
have more alterations in CNV between bins when compared to their PicoPlex alternatives 
(Figure 3) such as aberrant gains/losses in chromosomes 4p, 5, 8, 16, 19, and 20 in MP41 
Repli-G Cell 2 (Figure 6c). 
Figure 5: Assessment of Cell Processing on Genomic Quality. To test whether 
processing the cells would affect the genomic profile of the cell after amplification with 
PicoPlex we sequenced a) MP41 gDNA, b) 1 fixed MP41 cell, and c-f) 3 fixed, 
permeabilised, and stained MP41 cells and 1 healthy donor PBMC. We found that after 
immunomagnetic isolation, fixation in 4% paraformaldehyde caused no aberrations to the 
genomic profile of the cell, and that fixation, permeabilisation, and staining had minor 
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alterations however the prognostic information was still clearly visible, however, there 
were alterations in chromosomes such as 2 and 12. 
Figure 6: Genomic Profile of a Single Circulating Tumour Cell Captured in a 
Patient with Primary Uveal Melanoma. a) Example of CTC captured. CTCs are heavily 
coated in immunomagnetic beads and fluoresce green, whereas PBMCs have few beads 
and fluoresce red. Image taken at 200x magnification. b) A single CTC found in a patient 
with primary UM was found after immunomagnetic isolation, fixation, permeabilisation, 
and staining. The CTC was captured and amplified using PicoPlex WGA and underwent 
low-pass WGS. The resultant genomic profile indicated a distinct gain of chromosome 8 
whilst the other chromosomes remained diploid, with several other chromosomes 
appearing to trend toward a detectable gain. 
Supplementary Figure 1: Cell Synchronisation by Serum Depletion:  Histograms 
displaying cell cycle gating and per cent of cells in each cell cycle phase. “MP41 Control” 
shows ~ 12.2% in S phase whilst “MP41 Starved” with serum depletion only had ~5.2% 
of cells in S phase. 
Supplementary Figure 2: Representative results of ddPCR histograms. GNA11 
Q209L assay was tested in samples amplified by a) Repli-G and b-c) PicoPlex. Blue dots 
represent mutant DNA positive drops, green dots represent wildtype DNA positive drops, 
orange dots represent both positive for mutant and wild type DNA, and black dots 
represent empty droplets. Loci are more consistently amplified in Repli-G samples a) than 
PicoPlex samples b-c).  
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Supplementary Data 
Supplementary Method 
Cell Cycle Synchronisation 
Prior to isolating and capturing single cells from UM cell lines for WGA, their cell cycles 
were synchronised to reduce the probability of capturing cells in S-phase, which can lead 
to the detection of DNA imbalances. For this, cells were cultured with serum-depleted 
RPMI 1640 for 16-18 hours at 37°C in a humidified 5% CO2 incubator. To evaluate that 
cells were synchronised we compared MP41 cells that were cultured in RPMI 1640 
medium containing FBS and MP41 cells that were cultured in serum-depleted RPMI 1640 
medium. MP41 cells were harvested using 5mM EDTA in RPMI 1640, washed twice 
with PBS, and fixed using 70% Ethanol in distilled water. Cells were incubated with 
propidium iodide and RNase A (Dako) for 10 minutes, washed 3 times in FACS buffer 
(PBS with 0.1% BSA, 25mM HEPES, 1mM EDTA, pH 7.0) prior to flow cytometric 
analysis on a Gallios Flow Cytometer (Beckman Coulter) and analysed with the Kaluza 
software package (Beckman Coulter). 
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6.0 General Discussion 
The ability to predict the metastatic risk of patients with primary UM is essential for 
delineation of UM patients at higher risk, to provide personalised monitoring strategies 
and for the testing and implementation of adjuvant therapies to prevent metastatic disease. 
Unfortunately, despite the availability of molecular profiling methods for accurate 
prediction of metastatic risk, tumour biopsy is only occasionally performed. Vision 
threatening complications associated with acquisition of tumour tissue through an 
invasive procedure, combined with the current lack of effective therapies precludes many 
patients from consenting to the test. Implementation of an alternative, safer method of 
predicting patient prognosis is paramount to enable adjuvant therapy clinical trials.  
Through this study, we aimed to establish a methodology to make use of CTCs as an 
accessible source of tumour material for genetic profiling and prognosis of UM (Figure 
14). First, we evaluated melanocyte, melanoma, and stem cell markers on a primary UM 
TMA and 5 UM cell lines to find markers that were highly expressed. After determining 
5HT2B, ABCB5, gp100, MCAM, and MCSP were suitable extracellular markers for 
targeting UM cells, we tested their rate of capture in UM cell lines. We discover that 
certain markers provided a low (5HT2B and ACBC5) and others a moderate (gp100, 
MCAM, and MCSP) capture rate. Furthermore, we used UM cell lines to validate that the 
methods of processing the cells for detection of CTCs followed by WGA does not cause 
changes to the genomic profile of the cell, when assessed by WGS. Once these criteria 
had been established we determined that single CTC isolation was an effective means of 
determining CNVs found in UM.  
 
Figure 14: Pipeline of Circulating Tumour Cell Analysis in Patients. Pipeline of 
utilising CTCs as an alternative to a biopsy. Blood is drawn prior to radiation plaque 
insertion, followed by isolation and capture of CTCs, followed by WGA and WGS of 
captured CTCs WGS data is analysed to give a whole genome CNV report. 
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Capture and identification of UM CTCs poses significant challenges. Previous literature 
indicates that single markers such as MCSP (Suesskind et al., 2011) and MCAM (Bande 
et al., 2015) alone are not sufficient for a viable alternative to tissue biopsy. More recently, 
Tura et al (2014) demonstrated that by using two markers, CD63 and surface gp100, that 
they could capture a median density of 3.5 CTCs with a range of 0-10.2 cells per 10 mL 
of blood in 93.5% of patients with primary UM. This result demonstrated that a multi-
marker immunomagnetic enrichment protocol was capable of significantly improving 
CTC capture in patients. Using this knowledge, we added surface gp100 (NKI/BETEB) 
to the multi-marker capture of CTCs. Conversely, although CD63 is a highly important 
protein in melanogenesis (van Niel et al., 2011), and highly expressed in UM (Cools-
Lartigue et al., 2008), we opted to avoid CD63 due to its high expression on non-
melanoma cells (Human Protein Atlas available from www.proteinatlas.org, (Uhlen et 
al., 2015)) and microvesicles (Andreu and Yáñez-Mó, 2014), which may lead to higher 
background of non-melanoma cells/microvesicles captured. This could confound the 
analysis of single CTCs by contaminating them with other sources of extracellular DNA. 
Therefore, we targeted markers that are primarily expressed in melanocytes, melanoma, 
and stem cells to avoid this issue. Our preliminary data suggests that our multi-marker 
panel, comprising of 5HT2B, ABCB5, surface gp100, MCAM, and MCSP is suitable for 
capturing CTCs in patients, although analysis of a large cohort of patients using our multi-
marker panel is required to fully determine the capture rate. 
Although we expect that our multi-marker approach will increase CTC capture rates, one 
noticeable limitation of analysing CTCs to predict patient prognosis, is that these may not 
be found in all patients. It is important to note that implementation of a CTC based test 
does not preclude patients from having the biopsy. The blood test should be performed 
prior to plaque insertion and if no CTCs are captured from the patient’s blood sample, 
there is still the option of a biopsy at the time of surgery. Therefore, our proposed pipeline 
of analysing single CTCs supplements the current standard of care rather than offering a 
replacement.  
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If CTCs are not found in the sample patients can opt for a biopsy which provides several 
options for analysis, after extraction of the DNA; i) the biopsy can be whole genome 
amplified and sequenced for detection of CNVs across the genome such as the example 
shown in Figure 15, ii) MLPA can be performed to detect CNVs in chromosomes 1p, 3, 
6, and 8, or lastly, iii) RNA can be extracted and gene expression profiling can be used to 
segregate patients into class Ia, Ib, or II (Figure 15). Moreover, DNA amplified could in 
future studies be used to detect mutations in BAP1, SF3B1, or EIF1AX to finer segregate 
patient prognosis. 
 
Figure 15: Proposed Circulating Tumour Cell ‘Liquid Biopsy’ Pipeline. Proposed 
pipeline of CTCs for prediction of patient prognosis. After blood collection and isolation 
of CTCs, WGA and WGS would be performed to detect CNV changes associated with 
prognosis. If no CTCs are found, patients are still able to request a biopsy at time of 
radiation plaque insertion. DNA or RNA would be extracted, followed by either i) WGA 
and WGS, or ii) MLPA to detect CNV changes associated with prognosis, or iii) gene 
expression analysis of RNA to segregate patients into class Ia, Ib, or II. 
Peripheral venous blood is a highly accessible, minimally invasive, and safe method of 
acquiring blood used for ‘liquid biopsies.’ However, recently it has been shown that 
arterial blood may harbour more CTCs than venous blood, with CTCs detected in 100% 
of metastatic UM patients (Terai et al., 2015). Generally, arterial blood is more difficult 
to acquire, and more invasive for the patient, but the overall benefit may be greater than 
the risk, especially when compared to the intraocular biopsy. Interestingly, Terai et al. 
(2015) used the CellSearch system for detection of CTCs which employs MCAM based 
capture and MCSP detection. This may indicate that similarly to current findings in 
venous blood (Tura et al., 2014; Tura et al., 2016), a multi-marker immunomagnetic panel 
might have a greater benefit in arterial blood by increasing the number of CTCs detected 
in each patient.  
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Whilst CTCs constitute a source of genetic material for use in predicting patient prognosis 
through CNVs, there has been no correlation between the numbers of CTCs quantified 
and patient outcomes (Suesskind et al., 2011; Tura et al., 2014). In contrast, whilst we 
have shown ctDNA is rarely detectable in patients with primary UM, previous studies 
have detected ctDNA in 84% of patients with metastatic disease (Bidard et al., 2014). 
Therefore, tracking ctDNA in patients with tumours at a high risk of metastasizing may 
provide early indications that metastatic lesions have arisen, most likely within the liver 
(COMS-15, 2001). In other cancers, ctDNA has been used to measure tumour mutational 
load (Murtaza et al., 2013), residual disease (Diehl et al., 2008), resistance to therapy 
(Gray et al., 2015b), tumour burden (Bettegowda et al., 2014), tumour relapse (Garcia-
Murillas et al., 2015), and CNVs (Heitzer et al., 2013b). Fortunately, the majority of UM 
have hot spot mutations in GNAQ, GNA11, PLCβ4, or CYSLTR2 which are easily 
detectable using technologies such as ddPCR. This combination of all these markers 
could allow for analysis of ctDNA without prior knowledge of the mutational status of 
the tumours in the majority of cases as approximately 94% of patients have a mutation in 
these hotspots (Moore et al., 2016). However, a negative result always will have to be 
regarded as negative only for the tested mutations and not the lack of ctDNA. 
Nevertheless, the use of these mutations enables tracking of ctDNA regardless of whether 
a patient’s primary or metastatic lesions were biopsied. Further studies are required to 
ascertain whether ctDNA can be used as an early indicator of metastatic disease and that 
it is comparable or superior to current tests such as positron emission tomography or 
magnetic resonance imaging.  
Recent data has shown that fine-needle biopsies via transcorneal, transscleral, or 
transvitreal have a true positive rate of 92% when using cellularity to diagnose UM. 
Moreover, prognostication using FISH could only be performed on 84.6% of fine needle 
biopsies due to the lack of cells (Singh et al., 2016). Factors that improved prognostic 
yield were enucleation, larger tumour size, and distance from fovea. Additionally, 
patients who required transvitreal or transcorneal biopsy had a greater rate of failure when 
compared to transscleral (68.8%, 87.5%, and 98.6% respectively) (Singh et al., 2016). It 
is currently unknown the failure rate of using CTCs as a minimally invasive liquid biopsy, 
but we envisage it to be used as an alternative to tumour biopsy. If the liquid biopsy 
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produces inconclusive results an intraocular biopsy can still be performed at the time of 
radiation plaque insertion. 
Mutations in BAP1, SF3B1, and EIF1AX can further stratify patients into more refined 
prognostic classes (Field et al., 2016). Detection of these mutations in PicoPlex WGA 
proved to be challenging, due to the size of PicoPlex product (~400bp), and that targeted 
or whole exome sequencing requires primers to synthesise fragments for sequencing and 
these may not overlap correctly in the small DNA fragments produced by PicoPlex to 
produce an amplicon. Our preliminary data in testing targeted sequencing of a PicoPlex 
WGA-DNA using Ampliseq gave extremely erroneous results. Furthermore, primerless 
whole genome sequencing at a suitable depth to analyse mutations is currently 
prohibitively expensive. Fortunately, sequencing costs are continually decreasing, 
according to the National Institute of Health (NIH), and further refinement of high 
throughput sequencing may further reduce the per-genome cost of sequencing 
Overall, the primary objective of a less invasive method of determining patient prognosis 
is to reduce the complications associated with biopsy, and to encourage more patients to 
determine their prognosis. If patient prognosis has been determined the implementation 
of neo-adjuvant therapies, adjuvant therapies, closer follow-up, or even entry into clinical 
trials can occur. Current clinical trials into adjuvant therapies, targeted therapies, and 
immunotherapies all require prior information on a patient’s risk of developing metastatic 
disease (Appendix 8.3 & 8.4). Recent clinical trials show slight benefits to patients 
utilising targeted therapies (Selumetinib, 2013), whereas immunotherapies generally 
have little to no effect (Algazi et al., 2016; Moser et al., 2015). Adjuvant therapy has 
previously been reported to have survival benefits in various cancers, such as breast (Goss 
et al., 2005) and colon (Ribic et al., 2003; Schmoll et al., 2015) cancers. Although there 
is no evidence that current adjuvant therapies for UM have any impact on survival of 
patients with high risk of developing metastasis, current and future trials of different drugs 
may find a survival benefit or preferably preclude metastatic disease in patients, and 
therefore it would be beneficial for all patients to know their prognosis so that they may 
partake in clinical trials, or therapies which may provide them with improved quality of 
life. 
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6.1 Limitations 
A limitation of this study is the sample cohort. As UM is a rare disease, in an area with a 
low population (approximately 1.8 million people in Perth, Western Australia) it is 
difficult to gain the appropriate numbers for in-depth analysis. A multicentre study from 
various locations in Australia would be crucial for determining the concordance between 
the genetic characteristics of CTCs and their correlation with the primary tumour and 
patient prognosis.  
Similarly, due to the timeframe of a Masters project, and first having to validate all the 
methods used to analyse single CTCs, we were only able to capture 1 CTC in a single 
patient. To further validate whether CTCs can represent the primary tissue and thus the 
risk of metastatic risk in patients, further CTC analysis in a larger cohort of patients is 
required. 
In addition, the use of a TMA for the primary tissue may have caused an under or over 
representation of the immunopositivity of proteins, due to the 1 mm cores. Although care 
was taken to acquire tissue in histologically distinct areas of the tumour, the overall small 
size of the cores gives a small snapshot of the tumour. For example, if a marker is highly 
expressed on the tumour invading front, it may be under represented in our study, as the 
edges of the tumours were avoided. This is however, offset by using multiple cores per 
tumour in different areas. TMA’s are routinely used due to their benefits of screening a 
higher number of patients more efficiently and we found the TMA to be of significant 
benefit for assessment of markers. 
Whilst we have shown in cell lines PicoPlex introduces only minor changes to ploidy 
across the genome, if these changes occur in chromosomes relating to metastatic risk it 
could alter the prognostic call. This would introduce false positive results. Fortunately, 
our testing indicates that the amplification method is quite robust and unless the reaction 
failed, the resultant WGA-DNA harboured a match to the original material. It is also 
important to note an additional limitation to our study was that the amplification of cells 
unfixed, fixed, and fixed-permeabilised and stained was performed with different 
passages of MP41 cells and the changes could be due to the effects of cell culture. By 
attempting to capture more than 1 CTC per patient we aim to obtain consistent 
chromosomal CNV across various cells to remove any random CNV introduced as an 
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artefact. Nevertheless, in our preliminary data, sequenced PBMCs from patients have all 
displayed the correct ploidy. Further studies will provide a larger cohort of sequenced 
WGA cells and provide a better indication of the false positive rate. 
6.2 Future Directions 
Following on from this study we will focus on determining whether CTCs can predict 
patient prognosis as do current methods such as gene expression profiling or MLPA, 
however these require tissue biopsies. To assess CTC concordance with tissue analysis, a 
prospectively designed study would be carried out, where peripheral blood samples and 
matched biopsies would be taken and genotyped prior to therapy of the primary tumour, 
and patients would be followed over a >3-year period.  
In addition, future studies will involve pre-clinical mouse models where dissemination of 
CTCs from the primary tumour will be modulated with various drug combinations to try 
and disrupt metastases forming in the liver. These experiments could provide clear 
answers of the potential benefit of adjuvant therapy to prevent metastatic UM in at risk 
patients. 
6.3 Conclusion 
Our study validated 5HT2B, ABCB5, gp100, MCAM, and MCSP as highly expressed in 
UM and suitable candidates for capture of CTCs in patients with primary UM. 
Furthermore, we validated the use of PicoPlex WGA and low-pass WGS as an effective 
means of whole genome CNV analysis of CTCs that have been immunomagnetically 
enriched from PBMCs, fixed, permeabilised, and immunostained. Using this pipeline of 
a multi-marker immunomagnetic enrichment protocol, we were able to determine in a 
single patient a gain of the chromosome 8, a poor prognostic feature in UM.  
It is clear that our study has established an effective means of utilising CTCs to detect 
chromosomal aberrations associated with metastatic risk in UM. Future studies will 
validate this methodology in which CTCs can be used as an alternative source of tumour 
genetic material from which patient prognosis can be derived, therefore potentially 
reducing complications associated with biopsy of the eye, while providing more patients 
at a high risk of developing metastases the option of closer follow-up, and possible 
adjuvant therapy options. 
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8.0 Appendices 
8.1 Study Ethics Information and Consent Form 
PARTICIPANT INFORMATION SHEET 
 
Identification of markers for diagnosis and prognosis of cancer  
 
Prof Mel Ziman, Prof Michael Millward, A/Professor Fred Chen, Dr Tim Isaacs, Dr Chris 
Quirk, Dr Adnan Khattak, Dr Lester Cowell, Dr Graham Potter, Dr David Prentice, Mr 
Mark Lee, Prof Robert Pearce, Ms Anna Reid, Mr James Freeman, Dr Elin Gray, Ms 
Pauline Zaenker, Ms Kit Dufall, Dr Johan Poole-Johnson, Dr Arif Anwar, Mrs Ashleigh 
McEvoy, Dr Henry Law, Dr Carlos Aya-Bonilla, Mr Aaron Beasley. 
 Please take time to read the following information carefully and discuss it with your 
friends, family and general practitioner if you wish.  Ask us any question if some part of 
the information is not clear to you or if you would like more information. Please do this 
before you sign this consent form.   
Who is funding this study? 
NHMRC, Cancer Research Trust, Edith Cowan University 
Contact persons: 
Should you have questions about the study you may contact: 
 
Prof. Mel Ziman  Phone No. 6304 3640 Mobile: 0419929851 
 
 
All study participants will be provided with a copy of the Information Sheet and Consent 
Form. They may keep the information sheet for their personal records. 
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You may decide to be in the study or not take part at all. If you do decide to take part in 
this study, you may stop at any time.  However, before you decide, it is important that 
you understand why this research is being done and what it will involve.  
Whatever your decision, this decision will not lead to any penalty or affect your regular 
medical care or any benefit to which you are otherwise entitled.  
The following information sheet will explain the study and will include details such 
as: 
o Why this trial might be suitable for you; 
o The possible risks (side-effects) and benefits of the new test; 
o The type, frequency and risks of any medical tests or procedures required by the 
trial; 
o The nature of your participation including how many visits you will make to the 
hospital 
o Your rights and responsibilities 
o Who is funding this study 
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What is the purpose of the study? 
This study is a research project in which we are investigating circulating tumour cells 
(CTCs), gene expression (RNA), cell free DNA and proteins in the peripheral blood of 
patients with cancer relative to these markers in tumour tissue and in control bloods. It is 
anticipated that changes in cellular, genetic or protein markers in the blood of patients are 
indicative of tumour presence (diagnostic) or may provide information on patient 
outcome or tumour progression (prognostic) or response to treatment. 
We will isolate and quantify circulating tumour cells and genetic material (DNA and 
RNA), as well as proteins and sugars from the blood of all participants. We will 
characterise the cells, genes and proteins and sugars for markers of cancer.  
If we find that there are circulating tumour cells in your blood, we may ask your consent 
to isolate and grow the isolated circulating tumour cells and use them for laboratory 
experiments. We may ask your consent to access a small amount of your archival tumour 
tissue stored at Pathology Centres or fresh tissue at the time of surgical removal or biopsy 
for routine pathological diagnosis. We only require a small portion of your tumour that is 
additional to that required for pathological diagnosis. Tumour tissue may include both 
primary and metastatic tissue samples where appropriate. DNA from your circulating 
cells and tumour tissue will be compared for mutation analysis. We will also isolate 
proteins from your blood for analysis relative to control samples.  
1500 participants will be invited to participate.  
Why is this study suitable to me? 
You have been invited to participate in this study because you have been diagnosed with 
cancer. 
How long will I be in this study? 
The study will be conducted over a five year period. As a patient you will be asked to 
provide a blood sample at the time of surgical removal of your tumour or at the 
commencement of additional therapy and at follow-up.   
As a patient you may also be asked to provide consent for us to access a small amount of 
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your tumour tissue which has been stored at Pathology Centres after being used for 
diagnosis. Alternately you may be asked to provide a small sample of fresh tumour tissue 
at time of removal or biopsy of your tumour. 
What will happen if I decide to be in this study? 
If you agree to participate you will be asked to provide blood samples at the time of 
surgical removal of your tumour or before and during treatment, where appropriate. You 
will be asked to provide additional blood samples at the time of routine clinical follow-
up visits to your clinician. 
The amount of blood required for this study is small (approximately 40 ml per visit). 
Blood will be drawn into 8 x 4 ml EDTA blood tubes and 1 x 4 ml SST tube, for isolation 
of the circulating cells and for analysing genes, proteins and sugars in your blood.  
Generally you will not be contacted between visits. If you require general information 
about the research at any time then you are able to contact the researchers should you 
wish to do so. Contact details are provided in the information sheet. 
Your blood will be tested relative to blood from other participants. Your samples are only 
identifiable by a coded number, and the researchers performing the tests will not know 
which samples are yours. 
Your samples will be stored in locked freezers in secure research laboratories during the 
research study and will be discarded five years after completion of the study or upon your 
written request. 
Are there any reasons I should not be in this study? 
The clinical staff collaborating in this study will discuss the research with you in detail 
and will ensure that this trial is both safe and appropriate for you. 
What are the costs to me? 
There will be no additional costs over and above your visits to the doctor. Blood will be 
taken at the hospital or private clinical practice or at Edith Cowan University when and 
where you visit your doctor for treatment and follow-up visits.  Your tumour tissue may 
be required for comparison with your blood sample and your tissue will be accessed 
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through clinicians and pathology centres and will be extra tissue that is not required for 
diagnosis. 
What are the possible benefits of taking part?  
The results of these studies may be of interest to you and your family and you may decide 
whether or not the information may be disclosed to your family. You will be provided 
with the results of the project in general.  However, the research will not provide you with 
any detailed information about your health or genetic diseases in general.  
Donation of your sample may assist researchers to provide a more detailed and specific 
diagnosis of cancer now and in the future and to assist with improvements in treatment of 
cancer. 
How will my safety be ensured? 
In this study, the samples that you provide are blood samples and you may also be asked 
to provide permission to access a small quantity of your tissue sample(s). There is very 
little risk to you as only a small volume of blood is required for the test and the tissue has 
already been removed during surgery. However ple 
ase do not hesitate to contact the study coordinator or your doctor in relation to any 
adverse effects you think you are experiencing. If the effects are severe enough, the doctor 
may stop your participation in the study.  
The study may produce abnormal results in which case your clinician will be notified and 
additional clinical tests will be performed if your doctor feels it is in your best medical 
interest.  When you stop participation in the study you will be clinically assessed as you 
were at the beginning of the study. 
What alternatives do I have to going on this study? 
This study does not affect your treatment. Your treatment will continue in the same 
manner whether you decide to participate in the study or not.  
You may wish to discuss with your doctor or the researchers how the test will benefit 
patient treatment now or in the future.  
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What are the possible side effects, risks and discomforts of taking part? 
In this study, only a small volume of blood is taken (40 ml), so there is very little risk to 
you in this procedure. You may suffer a small amount of discomfort when you donate the 
blood sample, like the feeling of a pin prick or bruising.  
The likelihood of side effects from donating blood is small, around 1 in 100. However 
should you suffer any side effects please tell your doctor immediately about any new or 
unusual symptoms that you get.  
What if new information comes along during the study? 
Sometimes new information becomes available as a study progresses. You will be told 
about any information that could be important to you and to your decision to continue in 
the study. If you then want to continue in the trial, you may be asked to sign a revised 
consent form. 
Stopping the study early: 
Sometimes a trial needs to be stopped early because of safety concerns, because the trial 
is not effective enough, or for other reasons. If this occurs, the reasons will be explained 
to you and your treatment will continue as it would have without the test. Your treatment 
will not be influenced by the test in any way. 
What happens at the end of the study? 
At the end of the study your visits to your doctor will continue and your treatment will 
not be affected by the outcome of the research.  
What if something goes wrong? 
You will receive the best medical care available during and after the test, but because 
these are still relatively new tests, unexpected results may be obtained. In the unlikely 
event of risks to your health being identified then you will be provided with the necessary 
care.  
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Medical treatment will be provided at no cost to you for research-related harm.  The term 
“research-related harm” means both physical and mental injury caused by the procedures 
required by the trial.  
Your participation in this study does not prejudice any right to compensation which you 
may have under statute or common law. 
Will my taking part in this study be kept confidential? 
The researchers will need to collect personal data about you, which may be sensitive, such 
as your relevant health information. This includes clinical records relating to the diagnosis 
and treatment of your cancer. The researchers may also need to get some of your health 
information from other health service providers, e.g. another hospital, pathology 
laboratory, radiographer, GP or other medical specialist. 
Any personal or health information will be kept private and confidential. It will be stored 
securely and only authorised persons, who understand it must be kept confidential, will 
have access to it. Your study details will be given a number so that your identity will not 
be apparent. The trial records will be kept at The School of Medical Sciences at Edith 
Cowan University during the study and in a locked archive for at least 10 years from the 
time the study is closed, and will be destroyed by incineration thereafter. 
Authorised representatives of the researchers, the investigating doctors, the Hospital or 
University Human Research Ethics Committees, Research Governance and other 
regulatory bodies may require access to your study records for study procedures and/or 
for data analysis. Your sample may be sent to people in other states or other countries for 
analysis, however your sample will be identified by a sample number only, and your name 
and personal details will not be provided. In all cases when dealing with your sample, 
personal or health information, researchers are required to comply with privacy laws that 
protect you. 
The result of the research will be made available to other doctors through medical journals 
or meetings, but you will not be identifiable in these communications. By taking part in 
this study you agree not to restrict the use of any data even if you withdraw. Your rights 
under any applicable data protection laws are not affected. Your sample will be destroyed 
upon written request if you withdraw from the study. 
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Will I find out the results of the study? 
The value of the research is not known at this time. You will be notified of the results of 
the research in general terms at your request and the outcomes of the research as a whole 
may be provided to you upon completion of the project. 
Who has reviewed the study? 
The Sir Charles Gairdner Hospital Human Research Ethics Committee and the Edith 
Cowan University Human Research Ethics Committee have reviewed this study and have 
given approval for conducting this research trial. In doing so this study conforms to the 
principles set out by the National Statement on Ethical Conduct in Research involving 
Humans and according to the Good Clinical Practice Guidelines. 
If you have any concerns or complaints and wish to talk to an independent person, please 
contact: 
Research Ethics Officer Phone: 6304 2170 Email: research.ethics@ecu.edu.au 
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                                   CONSENT FORM 
 
Identification of markers for diagnosis and prognosis of cancer  
 
Prof Mel Ziman, Prof. Michael Millward, A/Professor Fred Chen, Dr Tim Isaacs, Dr 
Chris Quirk, Dr Adnan Khattak, Dr Lester Cowell, Dr Graham Potter, Dr  David Prentice, 
Mr Mark Lee, Mr Robert Pearce, Ms. Anna Reid, Mr. James Freeman, Dr Elin Gray, Ms. 
Pauline Zaenker, Ms Kit Dufall, Dr Johan Poole-Johnson, Dr Arif, Anwar, Ms Ashleigh 
McEvoy, Mr Aaron Beasley. 
. 
 
Participant Name:_________________________________________ 
 
Date of Birth: _______________ 
 
Address: ------------------------------   Phone Number:---------------------------------- 
 
1. I have been given clear information (verbal and written) about this study and have 
been given time to consider whether I want to take part. 
 
2. I have been told about the possible advantages and risks of taking part in the study 
and I understand what I am being asked to do. 
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3. I have been able to have a member of my family or a friend with me while I was told 
about the study.  I have been able to ask questions and all questions have been 
answered satisfactorily. 
 
4. I know that I do not have to take part in the study and that I can withdraw at any time 
during the study without affecting my future medical care.  My participation in the 
study does not affect any right to compensation, which I may have under statute or 
common law. 
 
5. I agree to take part in this research study and for the data obtained to be published 
provided my name or other identifying information is not used. 
 
6. I provide consent for my medical history to be made available to the researchers. 
 
7. I provide consent for the researchers to access a small sample of blood (40mls) and if 
necessary, my tumour tissue that is additional to that required for diagnosis. 
 
8. I provide consent for my circulating tumour cells isolated from my peripheral blood 
to be used in laboratory experiments. 
 
9. I understand that my sample and associated data may be used for future cancer 
research by researchers at Edith Cowan University in collaboration with researchers 
from other universities. 
 
10. I consent to blood and tissue samples being taken and donate that blood and tissue 
absolutely for testing and research into cancer and related health areas. 
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11. I understand that access to my blood donation and tissue sample for research will only 
be released where the research project that wishes to use my blood donation and/or 
tissue sample has been approved by an Ethics Committee 
 
If you are unclear about anything you have read in the Participant Information Sheet or 
this Consent Form, please speak to your doctor before signing this Consent Form. 
 
 
Name of Participant    Signature of Participant                                Date 
 
 
Name of Investigator   Signature of Investigator           
Date 
 
The Sir Charles Gairdner Hospital and Edith Cowan University Human Research Ethics 
Committees have given ethics approval for this study. If you have any concerns you can 
contact the Chief Investigator, Prof Mel Ziman: Phone (08) 63043640 
 
All study participants will be provided with a copy of the Information Sheet and 
Consent Form for their personal records. 
 
  
121 
 
 
8.2 DecisionDx-UM Genes 
Symbol 
Gene 
Regulation in class 
II 
CDH1 E-cadherin Up 
ECM1 Extracellular matrix protein 1 Up 
E1F1B Eukaryotic translation initiation factor 1B Down 
FXR1 Fragile X mental retardation autosomal homolog 1 Down 
HTR2B 5-hydroxytryptamine (serotonin) receptor 2B Up 
ID2 Inhibitor of DNA binding 2 Down 
LMCD1 LIM and cysteine-rich domains 1 Down 
LTA4H Leukotriene A4 hydrolase Down 
MTUS1 Microtubule-associated tumor suppressor 1 Down 
RAB31 RAB31, member RAS oncogene family Up 
ROBO1 Roundabout, axon guidance receptor 1 Down 
SATB1 SATB homeobox 1 Down 
MRPS21 Mitochondrial ribosomal protein S21 Normal (Control) 
RBM23 RNA binding motif protein 23 Normal (Control) 
SAP130 Sin3A-associated protein Normal (Control) 
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8.3 Clinical Trials of Targeted Therapies for UM 
ClinicalTrials.gov 
Identifier 
Compound Tested Target Mutation 
Rationale 
NCT01430416 
NCT01801358 
AEB071 PKC GNAQ/11 
NCT01551459 
NCT01005472 
Sunitinib MEK GNAQ/11 
NCT01252251 
NCT01587352 
NCT00121225 
Everolimus 
Vorinostat 
mTOR 
HDAC 
GNAQ/11 
BAP1 
NCT01377025 
NCT01893099 
NCT00329641 
Sorafenib RAF-kinases GNAQ/11 
NCT01801358 
NCT01143402 
NCT01835145 
NCT00104884 
MEK162 
Selumetinib 
Cabozantinib 
Romidepsin 
MEK 
MEK 
MEK, KIT 
HDAC 
GNAQ/11 
GNAQ/11 
GNAQ/11 
BAP1 
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8.4 Adjuvant Therapy Clinical Trials for High Risk Patients 
Clinicaltrials.gov 
Identifier 
Compound Tested Primary Outcome 
Measure 
Secondary Outcome 
Measures 
NCT02843386 Fotemustin Metastasis free 
survival [3 yrs] 
Overall survival [3yrs] 
Safety 
NCT02068586 Sunitinib 
Valproic acid 
Overall survival [2 yrs] Relapse free survival 
[2yrs] 
Tolerability 
NCT01983748 Autologous dendritic cells 
loaded with autologous 
tumour RNA 
Prolongation of disease 
free survival [36 mths] 
Prolongation of overall 
survival [36 mths] 
NCT01100528 Recombinant interferon alfa-
2b 
Dacarbazine 
Laboratory biomarker 
analysis 
Disease free survival Safety 
Relationship between 
plasma biomarkers of 
immune function and 
tumour invasion and 
clinical outcome 
NCT02223819 Crizotinib Relapse free survival 
[36 mths] 
Overall survival [36 
mths] 
Disease specific 
survival time [36 mths] 
Prevalence of 
treatment 
discontinuation due to 
toxicity [48 wks] 
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8.5 COMS Staging System 
Measure Small Medium Large 
Apical Height  1.0-3.0 mm 3.1-8.0 mm >0.8 mm 
Basal Diameter 5.0-16.0 mm ≤16.0 mm >16.0 mm when apical 
height ≥2 mm 
(COMS-5, 1997; COMS-17, 2001) 
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8.6 AJCC Staging System 
Location 
Tumour 
Stage 
Description 
Iris 
T1 
T1a 
T1b 
T1c 
Limited to iris 
Limited to iris and <3 clock hours in size 
Limited to iris and >3 clock hours in size 
Limited to iris with secondary glaucoma 
T2 
T2a 
Extending into ciliary body, choroid or both 
Confluent with or extending into ciliary body, choroid or both and has secondary glaucoma 
T3 
T3a 
Scleral extension 
Confluent with or extending into ciliary body, choroid or both with  scleral extension 
T4 
T4a 
T4b 
Extrascleral extension 
Extrascleral extension ≤5 mm in diameter 
Extrascleral extension ≥5 mm in diameter 
Ciliary Body 
and Choroid 
T1 
T1a 
T1b 
T1c 
T1d 
Tumour size category 1 
No ciliary body involvement or extraocular extension 
Ciliary body involvement 
No ciliary body involvement, extraocular extension ≤5 mm in diameter  
Ciliary body involvement, extraocular extension ≥5 mm in diameter 
T2 
T2a 
T2b 
T2c 
T2d 
Tumour size category 2 
No ciliary body involvement or extraocular extension 
Ciliary body involvement 
No ciliary body involvement, extraocular extension ≤5 mm in diameter  
Ciliary body involvement, extraocular extension ≥5 mm in diameter 
T3 
T3a 
T3b 
T3c 
T3d 
Tumour size category 3 
No ciliary body involvement or extraocular extension 
Ciliary body involvement 
No ciliary body involvement, extraocular extension ≤5 mm in diameter  
Ciliary body involvement, extraocular extension ≥5 mm in diameter 
T4 
T4a 
T4b 
T4c 
T4d 
T4e 
Tumour size category 4 
No ciliary body involvement or extraocular extension 
Ciliary body involvement 
No ciliary body involvement, extraocular extension ≤5 mm in diameter  
Ciliary body involvement, extraocular extension ≥5 mm in diameter 
Any tumour size category with extraocular extension ≥5 mm in diameter 
Both 
N0 No regional lymph node metastasis 
N1 Regional lymph node metastasis 
M0 No distant metastasis 
M1 
M1a 
M1b 
M1c 
Distant metastasis 
Diameter of largest metastasis is ≤3 cm 
Diameter of largest metastasis is 3.1-8 cm 
Diameter of largest metastasis is ≥8 cm 
(Edge et al., 2010) 
 
